Anda di halaman 1dari 21

American Journal of Obstetrics and Gynecology (2006) 195, 91434

www.ajog.org

Understanding and managing HELLP syndrome: The integral role of aggressive glucocorticoids for mother and child
James N. Martin Jr, MD, Carl H. Rose, MD, Christian M. Briery, MD
Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, MS
Received for publication April 21, 2005; revised July 13, 2005; accepted August 18, 2005

KEY WORDS
HELLP syndrome Severe preeclampsia/ eclampsia Aggressive glucocorticoids/ corticosteroids Obstetric

Antepartum or postpartum HELLP syndrome constitutes an obstetric emergency that requires expert knowledge and management skills. The insidious and variable nature of disease presentation and progression challenges the clinician and complicates consensus on universally accepted diagnostic and classification criteria. A critical review of published research about this variant form of severe preeclampsia, focused primarily on what is known about the pathogenesis of this disorder as it relates to patient experience with corticosteroids for its management, leads to the conclusion that there is maternal-fetal benefit realized when potent glucocorticoids are aggressively used for its treatment. Although acknowledging the need for definitive multicenter trials to better define the limits of benefit and the presence of any maternal or fetal risk, and given an understanding of the nature of the disorder with its potential to cause considerable maternal morbidity and mortality, we recommend for the present that aggressively used potent glucocorticoids constitute the cornerstone of management for patients considered to have HELLP syndrome. 2006 Mosby, Inc. All rights reserved.

Recognition that a particularly potent form of preeclampsia-eclampsia exists has been evident since case reports rst appeared in the late nineteenth1 and early twentieth century.2-5 Between 1950 and 1980, several case series were published that related patients and poor obstetric outcomes to clinical and laboratory ndings that are consistent with what we recognize today as HELLP syndrome.6-17 Credit for formally consolidating the concept and creating the acronym of HELLP (H = hemolysis, EL = elevated liver enzymes and LP = low platelets) goes to Louis Weinstein who in 1982 reported

Reprints not available from the authors. 0002-9378/$ - see front matter 2006 Mosby, Inc. All rights reserved. doi:10.1016/j.ajog.2005.08.044

a group of 29 pregnant patients he considered to have a distinct subset of severe preeclampsia/eclampsia.18 All patients expressed ndings suggestive of microangiopathic hemolytic anemia with moderate-to-severe thrombocytopenia, misshapened erythrocytes on peripheral smear, and abnormal liver function tests usually in conjunction with epigastric pain, nausea, and vomiting. Severe hypertension and proteinuria were frequently coexistent as well. Since 1982 there has been an outpouring of obstetric literature seeking to better dene the pathogenesis, natural history, clinical spectrum, classication and management strategies for patients considered to have HELLP syndrome. Because the incidence of this disorder is low

Martin, Rose, and Briery (1-6 per 100019,20), most clinical research endeavors have been small, single institution case series or randomized trials. Until denitive large multicenter trials are undertaken, clinicians must rely on less robust information to guide patient care. Despite several recent comprehensive reviews on the subject of HELLP syndrome,21-24 none to date have examined the available data and patient experience primarily from the perspective of corticosteroid impact on disease expression and progression. The current review is constructed from this perspective, synthesizing and summarizing the pertinent English literature on HELLP syndrome to understand how corticosteroids appear to play an integral role in its management.

915 superfamily, Fas is a 36 to 45 kDa type I surface protein containing a single transmembrane region.46 It induces apoptosis by binding to Fas-ligand, a 40 kDa type II transmembrane protein of the tumor necrosis factor receptor family.47 In the context of pregnancy and patients with HELLP syndrome, apoptosis in liver tissue and cytotoxic activity for primary human hepatocytes has been reported in serum from patients with HELLP syndrome (CD95 ligand produced by placenta) that increases over time and in proportion to disease severity.45 In addition, caspases 3, 8, and 9 are all required to eect apoptotic cell death, and active forms of all 3 are detected in liver extracts of HELLP patients. Blocking of CD95 signaling reduces the hepatocytotoxic activity of HELLP serum. Thus, systemic CD95L is a placenta-derived humoral factor that is involved in the pathogenesis of HELLP syndrome. CD95L-rich membrane fragments or soluble CD95L are postulated by Strand et al45 to be shed into the maternal circulation as important progenitors in the pathogenesis of HELLP syndrome. The previously described ndings and the proposal that placenta-derived proteins damage hepatic cells are compatible with many other ndings that cast HELLP syndrome as a placenta-instigated, liver-targeted acute inammatory condition and disordered immunologic process.21 The similarity between HELLP syndrome and systemic inammatory response syndrome (SIRS) has been emphasized by several researchers.48-50 The perturbations present in patients who have HELLP syndrome develop may be additive to, or altered by, the pathophysiology leading to preeclampsia in general. A listing of some of the supportive evidence for these concepts is contained in Table I. Decreases in haptoglobin are a sequel, not an instigator of the vascular hemolytic process.68 In patients with HELLP syndrome, the metalloprotease ADAMTS-13 is not severely decient or undetectable as it is in many patients with thrombotic thrombocytopenic purpura (TTP).69,70 No genetic markers or evidence for association with thrombophilic or antiphospholipid disorders have been established.71-75

Pathogenesis and natural history


HELLP syndrome usually develops suddenly during pregnancy (27-37 weeks gestation) or in the immediate puerperium.25-28 As a form of severe preeclampsia, it likely has its origins in aberrant placental development, function, and ischemia-producing oxidative stress, which triggers the release of factor(s) that systematically injure the endothelium via activation of platelets, vasoconstrictors, and loss of normal pregnancy vascular relaxation.29-36 Although variable, HELLP syndrome onset and progression usually is rapid (35%-50% decrease in platelets per 24 hours; mean daily reduction of 40,000/mL platelets) as lactic acid dehydrogenase (LDH) and aminotransaminases (aspartate [AST] and alanine [ALT]) rise until 24 to 48 hours postpartum when laboratory values begin to recover.37-42 Absent corticosteroids, most patients (85%-90%) achieve platelelets 100,000/mL or greater within 6 to 8 days of delivery or within 72 hours of platelet nadir, and total LDH/ transaminases trend toward normal within 96 hours postpartum.37,41-43 Onset of disease occurs postpartum in approximately 15% to 25% of cases.25-28 Although most patients with HELLP syndrome eventually exhibit hypertension and proteinuria, these 2 major signs of severe preeclampsia bear no consistent relationship with laboratory parameters of the underlying vasculopathy.26-28,37,38 A variety of symptoms can be elicited that are ambiguous, subtle, and focused primarily on the gastrointestinal-hepatic systems.28 The central place that the liver occupies in the disorder of HELLP syndrome is an important clue to pathogenesis. Severe epigastric/right upper quadrant pain often heralds underlying rapidly progressive disease.44 The extent of periportal hepatocyte dysfunction or cell death in a given patient probably correlates with the severity of maternal illness. Recall that CD95 (APO-1, Fas)-mediated apoptosis of hepatocytes is a major pathogenic mechanism for liver disease in general.45 The Fas-Fas ligand system is a well-studied cell death system that can mediate apoptosis. As a member of the tumor necrosis factor receptor

Diagnosis
The diagnosis of HELLP syndrome is most assured in a pregnant patient with signs and symptoms of preeclampsia-eclampsia and a triad of laboratory abnormalities suggesting red cell trauma (H = hemolysis), hepatic damage and dysfunction (EL = elevated liver enzymes), and thrombocytopenia (LP = low platelets). The greater the extent of laboratory abnormalities, the greater is the physicians condence in the diagnosis. Thrombocytopenia may be the rst indicator of disease when the results of a complete blood count return to the physician. A platelet count less than 150,000/mL represents mild (100,000-150,000/mL), moderate (50,000100,000/mL), or severe (!50,000/mL) thrombocytopenia

916
Table I Research ndings contributory to an inammatory pathogenesis for HELLP syndrome

Martin, Rose, and Briery

Elevated serum concentrations of soluble Fas.51 Cytokine and neutrophil-mediated liver injury in necropsy liver specimens with strong staining for tumor necrosis factor-alpha and neutrophil elastase antibody.52 Leukocytosis proportionate to disease severity.53 Increased plasma concentrations of anaphylatoxins C3a and C5a.54 Decreased unstimulated neutrophil oxygen radical production possibly secondary to an exhausted cellular response.55 Abnormal circulating cytokine concentrations.52,56 Increased bioactive tumor necrosis factor alpha possibly secondary to immune injury of the vascular endothelium or muscle.57 Depression of both T- and B-cell potential and impaired monocyte handling of intracellular pathogens precedes clinical/laboratory disease by 1-2 wks.58 Decreased placental vascular endothelial growth factor (VEGF) expression in placentas from HELLP syndrome pregnancies59,60 analagous to decreased circulating levels of free VEGF and platelet-derived growth factor (PlGF) in preeclamptic patients without HELLP syndrome.61 Dysregulation of VEGF ligands and receptors with higher serum VEGF compared to healthy matched pregnant controls (but less elevated than patients with non-HELLP preeclampsia.62 Hypersensitivity to pressors using laser-doppler digital uxometry microcirculation studies.63 Substantially decreased vascular smooth muscle-relaxing adrenomedullin and calcitonin gene-related peptide messenger RNA in the placenta.64 Increased intracellular retention of cadherin-5.65 Increased plasma and red cell thiobarbituric acid reactive substances (TBARS) and glutathione peroxidase activity.66,67

in the nonpregnant as well as pregnant patient.76 Requiring a threshold of less than 100,000/mL to consider the diagnosis of thrombocytopenia is ill advised. Maternal morbidity doubles from 11% to more than 20% when patients with severe preeclampsia have mild thrombocytopenia develop in association with increasing LDH (R600 IU/L) and transaminases (AST and/or ALT R40 IU/L).21,27 Signicant pathology such as hepatic hemorrhage and rupture can rst appear in the patient with HELLP syndrome before the platelet count falls below 100,000/mL.28 Indeed, the onset of epigastric pain in patients who are eventually diagnosed with HELLP syndrome has occurred at a platelet count as high as 283,000/mL in our patient population (unpublished).

Erythrocyte injury and death


Evidence for hemolysis is the third laboratory criterion for HELLP syndrome. In addition to a progressive anemia, other laboratory evidence of hemolysis classically includes decreased serum levels of haptoglobin, increased serum total LDH 600 IU/L or greater,26,28 increased serum AST, increased serum indirect bilirubin, an abnormal peripheral smear showing variable amounts of disrupted or destroyed red blood cells (schistocytes, echinocytes, burr cells), and/or a declining hematocrit or hemoglobin. Depending on laboratory methodology, LDH thresholds for abnormal values begin between 200 and 600 IU/L.

Classication
Hepatic injury and dysfunction
In Weinsteins initial 1982 report, thresholds of what constituted abnormal serum levels of aspartate transaminase (AST), alanine transferase (ALT) and bilirubin to merit a diagnosis of HELLP syndrome were not stated.18 Most healthy pregnant patients in our hospital laboratory exhibited normal transaminase values less than 20 IU/L, with greater than 48 IU/L for AST 3 SD above the mean.27 A threshold for AST of 70 IU/L or greater to qualify for the diagnosis of HELLP syndrome when platelets are 100,000/mL or less has been consistently advocated by Martin et al21 and Sibai.22 Transaminase values between 40 and 70 IU/L reect borderline hepatic dysfunction regardless of the platelet count (especially in the 100,000-150,000/mL range).28 Glutathione S-transferase alpha has been proposed as a better marker for acute liver injury than the aminotransferases, but there has been limited work on this possibility.77 Classication systems have been created to enable physicians to identify patients at risk for signicant maternal morbidity, to guide therapeutic intervention and assess ecacy or outcome, and to provide a common platform for comparison of research results. The 2 most commonly used systems for diagnosis and classication were developed in the 1980s by investigators at the Universities of Tennessee and Mississippi (Table II). The Tennessee Classication78 denes true or complete HELLP syndrome if all of the following criteria are met: (1) moderate to severe thrombocytopenia with platelets 100,000/mL or less; (2) hepatic dysfunction with AST 70 IU/L or greater; and (3) evidence of hemolysis with an abnormal peripheral smear in addition to either total serum LDH 600 IU/L or greater or bilirubin 1.2 mg/dL or greater. The patient who exhibits some but not all of these parameters is termed partial or incomplete HELLP syndrome: ELLP syndrome (missing

Martin, Rose, and Briery


Table II 1 Classication systems of HELLP syndrome Mississippi classication21,36,46 Platelet count %50,000/mL AST or ALT R70 IU/L LDH R600 IU/L 50,000/mL %Platelet count %100,000/mL AST or ALT R70 IU/L LDH R600 IU/L 100,000/mL %Platelet count %150,000/mL AST or ALT R40 IU/L LDH R600 IU/L N/A Tennessee classication22,165 Platelet count %100,000/uL AST R70 IU/L LDH R600 IU/L

917

HELLP class

N/A

Partial HELLP/ incomplete HELLP

(Severe preeclampsia C one of the following: ELLP, EL, LP)

ELLP, Absence of hemolysis; EL, elevated liver functions; LP, low platelets.

evidence for hemolysis), EL syndrome (severe preeclampsia with mildly elevated liver enzymes only), HEL (hemolysis and elevated liver enzymes absent thrombocytopenia), or LP syndrome (low platelets syndrome as severe preeclampsia with thrombocytopenia, gestational thrombocytopenia, or immune thrombocytopenic purpura).22 Maternal and perinatal outcomes are progressively worse for patients with preeclampsia, partial HELLP syndrome, and complete HELLP syndrome, respectively.79 Incomplete criteria initially can progress to complete expression of HELLP syndrome. The Mississippi-Triple Class System for HELLP syndrome divides patients into 3 classes or groups that are based primarily on the platelet portion of the laboratory diagnosis.21,28,38 Final class assignment or diagnosis is based on the lowest platelet count registered during the disease course. The span of thrombocytopenia between zero and 150,000 platelets is divided into 3 equal ranges consistent with mild, moderate, and severe thrombocytopenia. For a patient to merit a diagnosis of HELLP syndrome, class 1 requires severe thrombocytopenia (platelets %50,000/mL), evidence of hepatic dysfunction (AST and/or ALT R70 IU/L), and evidence suggestive of hemolysis (total serum LDH R600 IU/L); class 2 requires similar criteria except thrombocytopenia is moderate (O50,000 to %100,000/mL); and class 3 includes patients with mild thrombocytopenia (platelets O100,000 but %150,000/mL), mild hepatic dysfunction (AST and/or ALT R40 IU/L), and hemolysis (total serum LDH R600 IU/L). Peripheral smear ndings and bilirubin abnormalities are not obtained. Neither classication system is ideal; both have shortcomings. Because class 1 and 2 HELLP syndrome patients are combined in the Tennessee system, discrimination between groups and outcomes is dicult and benet from corticosteroids (arrest of disease in class 2, prevention of progression from class 3 to 2 or even 1) cannot be demonstrated. On the other hand, the Mississippi classication system is very useful for directing

individual patient therapy with aggressive corticosteroids and for comparing pregnancy outcomes. The Mississippi system, although including class 3 patients, does not include those with incomplete or partial forms of the disease, and excludes patients from analysis when causes of consumptive coagulopathy such as placental abruption are present. Two (Tennessee) or even 3 (Mississippi) groupings or classes insuciently describe the multitude of clinical scenarios (antepartum vs postpartum, epigastric pain present or absent, degrees of laboratory value abnormality, dierent gestational age epochs) encountered by the clinician. The importance of a transitional group of patients is clearly demonstrated by instances of hepatic ruptures in patients with class 3 HELLP syndrome80 and other reports of increased eclampsia and higher perinatal morbidity/mortality in patients with incomplete/partial HELLP syndrome.21

Imitators of HELLP Syndrome


Patients presumptively diagnosed with HELLP syndrome can have other disorders concurrent with HELLP syndrome or other disorders altogether. Lack of response to aggressive corticosteroid administration, especially with persistence of disease or rst presentation of disease more than 7 days after delivery, should instigate testing to evaluate other diagnostic possibilities (Table III). In our experience, the most common HELLP imitators are patients with well-advanced acute fatty liver of pregnancy (AFLP), acute renal failure with acute tubular necrosis (usually not hemolytic uremic syndrome), neglected class 1 HELLP syndrome coming to medical attention too late for aggressive corticosteroids to prevent progression and multiorgan dysfunction, previously undiagnosed systemic lupus erythematosus/antiphospholipid syndrome, and either immune thrombocytopenic purpura (ITP) or thrombotic thrombocytopenic purpura (TTP).98 See the excellent reviews of potentially confounding conditions written by Goodlin16,99 and Sibai.100

918
Table III Confounders and concurrent conditions: differential diagnosis50,134 AFLP81 Lupus are: Exacerbation of systemic lupus erythematosus (SLE)82,83 TTP84 Hemolytic uremic syndrome (HUS)85 ITP Thrombophilias Antiphospholipid syndrome75,83,86-91 Homozygous factor V Leiden Prothrombin gene mutation Severe folate deciency92 Cholangitis/cholecystitis/pancreatitis/ruptured bile duct Gastric ulcer Cardiomyopathy Dissecting aortic aneurysm Systemic viral sepsis (herpes, cytomegalovirus)93 SIRS/sepsis Hemorrhagic or hypotensive shock Stroke in pregnancy or puerperium Paroxysmal nocturnal hemoglobinuria94 Pheochromocytoma Advanced embryonal cell carcinoma of the liver95 Acute cocaine intoxication Myasthenia gravis96 Pseudocholinesterase deciency97

Martin, Rose, and Briery


Table IV Admission risk factors for signicant maternal morbidity/mortality HELLP syndrome Signs/symptoms Epigastric pain Nausea Vomiting Severe systolic hypertension Severe diastolic hypertension Placental abruption Eclampsia
Adapted from Martin et al.102

Laboratory values Platelets !50,000/mL Total serum LDH O1400 IU/L AST O150 IU/L ALT O100 IU/L Uric acid O7.8 mg/dL CPK O200 IU/L Serum creatinine O1.0

Clinical presentation
Signs and symptoms with HELLP syndrome are variable but depend largely on the stage of the patients disease, whether class 1, class 2, or class 3.28 Right upper quadrant/epigastric pain is the most important symptom suggestive of underlying HELLP syndrome, found in 100% of Weinsteins initial 1982 series of 29 advanced cases.18 Half of patients with class 1 HELLP syndrome, 33% with class 2, and 16% with class 3 compared with only 13% of severely preeclamptic patients without HELLP syndrome exhibit epigastric pain or right upper quadrant discomfort.28 Frequently epigastric pain occurs in association with nausea or vomiting. Overall, the incidence of epigastric pain/nausea/vomiting ranges between 30% and 90%.20,22,26 Any pregnant patient presenting in the second half of gestation with epigastric or right upper quadrant pain, particularly if associated with nausea and/or vomiting, has HELLP syndrome until proven otherwise.44 A pregnant patient with signs and symptoms of severe preeclampsia who suddenly has severe, writhing epigastric/upper abdominal pain develop likely has hepatic bleeding or rupture constituting an obstetric emergency. Malaise or viral syndrome-like symptoms can occur with advanced HELLP syndrome.22,26 Headache occurs in a substantial number (33%-68%)22,28 of patients with any form of preeclampsia whether HELLP syndrome is present, with visual complaints in a lesser number.22

Hypertension and proteinuria are not always present.21,22,101 Neither of these signs bears a consistent relationship in the individual patient with stage of disease, although on a population basis higher blood pressures and more proteinuria tend to occur more frequently as HELLP syndrome worsens from class 3 to 2 to 121,28,102 and eventually almost all patients are mildly hypertensive during the course of their disease and recovery.28 Signicant dipstick proteinuria (3-4C) at presentation occurs in approximately half of patients with class 1 or 2 HELLP syndrome, but no proteinuria is detected in approximately 1:6 patients. Although the presence and severity of symptomatology (epigastric pain, nausea, vomiting) and hypertension (systolic, diastolic) in general are related to maternal disease severity and the potential to develop severe morbidity,28,38,103 individual patient predictive value (with the probable exception of severe epigastric pain) is low.104 Signicant maternal morbidity becomes more likely when 1 or more of the laboratory thresholds are exceeded as listed in Table IV.102,105,106 Very high LDH, AST, and/or uric acid have the highest predictive value and are risk-additive with worsening thrombocytopenia.28,107

Maternal morbidity and mortality


The development of HELLP syndrome places the pregnant patient at signicant risk for morbidity and mortality. Morbidity is categorized by major organ system(s) aected and is stratied by extent of disease using the Mississippi classication system.28 Constituents of these categories are listed in Table V and presented in decreasing order of frequency, emphasizing that there is enormous variability among patients.

Hematologic-coagulation
The prevalence of disseminated intravascular coagulation (DIC) increased from 2 of 193 patients (0.5%) with severe preeclampsia to 35 of 201 (17.4%) with class 1 HELLP syndrome,28 the latter very similar to the 15% incidence of DIC and 9% incidence of placental abruption reported by Audibert et al79 for classes 1

Martin, Rose, and Briery and 2 combined. Clinically signicant bleeding requiring transfusion and wound hematoma formation follow a similar pattern of increasing incidence with worsening disease.21,25-28,79,104,108 Approximately 10% of patients with class 1 or 2 HELLP syndrome exhibit microscopic or macroscopic hematuria.28

919
Table V Categories of signicant maternal morbidity with HELLP syndrome Hematologic/coagulation Clinically signicant bleeding requiring transfusion Ecchymoses Hematoma DIC Hematuria Cardiopulmonary Cardiogenic/noncardiogenic pulmonary edema Cardiac/pulmonary arrest Pulmonary embolus Indicated invasive hemodynamic monitoring Intubation/mechanical ventilation/continuous positive airway pressure Myocardial ischemia/chest pain CNS/vision Cerebral hemorrhage/stroke Central venous thrombosis Hypertensive encephalopathy Cerebral edema Sensorium change/coma Impaired vision Retinal/macular detachment Vitreal hemorrhage Cortical blindness Eclamptic seizure Renal Acute tubular necrosis Acute renal failure Renal dialysis Transient renal impairment Hepatic Subcapsular/intrahepatic hematoma Hepatic rupture/hemorrhage Pancreatitis Infection/sepsis Obstetric Other

Cardiopulmonary
The odds of developing a cardiopulmonary problem, particularly pulmonary edema, is more than doubled (2.2!) for patients with class 1 HELLP syndrome (22%) compared with non-HELLP severe preeclampsia.28,109 The overall percentage of 14.5% (74/501) in the Mississippi series is similar to the combined 8% incidence of pulmonary edema and less than 1% incidence of adult respiratory distress syndrome in the Tennessee series.79 Copious large volume ascites identies a patient at high risk for cardiopulmonary complications.110

Central nervous system/visual


Patients with noneclamptic class 1 or 2 HELLP syndrome (11/501 or 2.2%) are 3.5 times more likely to have signicant central nervous system (CNS) morbidity compared with class 3 HELLP syndrome or non-HELLP severe preeclampsia.28 This includes stroke, mental status changes and/or coma.111-114 Visual complications including retinal detachment, vitreal hemorrhage, and cortical blindness are infrequent in proportion to disease severity (1.4% in class 1 and 2).28 These are usually short lived with full recovery within 1 to 6 months, except when cerebral hemorrhage/stroke is the cause.115-126

Renal
Placental abruption and puerperal onset of HELLP syndrome place the patient at increased risk for renal insult. In general, renal system morbidity increases as disease status worsens.28 All 4 of the patients with acute tubular necrosis in the Mississippi series had class 1 HELLP syndrome develop; acute renal failure complicated 3% of cases of class 1 or 2 HELLP syndrome in the Tennessee series.26,79 However, acute renal dysfunction and/or failure has been described as often as 54% and 33% in some international series19,127 and as the most common cause of maternal morbidity in a report from Mexico.128

Mississippi seriesdimportantly all were classied as class 3 HELLP syndrome when the complication was rst detected.27 According to Wicke et al,129 at least 1 of 5 patients with eventual liver rupture caused by HELLP syndrome had early subcapsular liver hematoma formation compatible with the class 3 level of disease.

Infection/sepsis
Patients with HELLP syndrome more often have infectious morbidity develop than those with non-HELLP severe preeclampsia (43% vs 20%).25,27 At least 3 important variables are involved: corticosteroids, transfusion, and delivery. Corticosteroid utilization appears to reduce infectious morbidity from 43% to 18% by reducing or eliminating the need for transfusion of blood products.27,28 Abdominal delivery doubles infectious morbidity from 19% to 41%.28

Hepatic
Catastrophic liver complications are relatively infrequent. Liver hemorrhage/rupture aected only 1% of patients with class 1 or 2 HELLP syndrome in the Tennessee series26,79 and only 3 patients had signicant hepatic complications develop (2 subcapsular hematomas in class 2 and 3 HELLP syndrome patients, 1 liver rupture in a class 1 HELLP syndrome patient) in the

920

Martin, Rose, and Briery

Figure 1 Contributing factors to deaths of women with HELLP syndrome are shown in order of decreasing frequency. DIC, Disseminated coagulopathy; ARDS, adult respiratory distress syndrome; Enceph, encephalopathy. Reprinted from Isler CM, Rinehart BK, Terrone DA, Martin RW, Magann EF, Martin JN. Maternal mortality associated with HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol 1999;181:924-8 with permission from Elsevier.

Obstetric issues
Cesarean delivery has been performed more often for patients with class 1 HELLP syndrome (61%) than class 2 (57%), class 3 (53%), or non-HELLP severe preeclampsia (48%).25,28 Mode of delivery is strongly inuenced by gestational age, maternal-fetal status, class of disease, and corticosteroid utilization. Overall abdominal delivery is associated with a doubling of maternal morbidity (cardiopulmonary, hematologic-coagulation, and infectious) compared with vaginal delivery.28 In addition, risk for placental abruption, placenta previa, eclampsia, and episiotomy breakdown is increased compared to non-HELLP pregnancies.20,25,130,131

associated with acute fatty liver of pregnancy.134 Diabetes insipidus,135 bone marrow necrosis with cerebral hemorrhage,88 and myocardial infarction136 are rare complications.

Mortality
Most deaths in patients with HELLP syndrome occur with class 1 disease (60%), and neurologic abnormality due mostly to cerebral hemorrhage/stroke is the most common system involved at autopsy (45%) (Figure 1).137 Delay in diagnosis appeared to be a factor in half of the deaths that could be adequately evaluated, and none of the 54 maternal deaths in the Isler et al series137 or in a subsequent case report138 occurred in association with the aggressive use of corticosteroids.

Parity-eclampsia
The incidence of complications in hypertensive pregnant women varies by parity but not by gravidity.132 When HELLP syndrome complicates eclampsia, parous patients have double the incidence of signicant maternal morbidity compared with nulliparous patients (50% vs 25%).133

Perinatal morbidity and mortality


Perinatal morbidity and mortality are substantially higher in pregnancies with severe preeclampsia complicated by HELLP syndrome, primarily because of required preterm delivery.25,139 Fetal growth restriction and fetal distress after 32 weeks also may be more frequent.140 Although neonatal deaths and perinatal mortality rates tend to be progressively higher in parallel with increasingly severity of disease, outcomes are

Other morbidity
Pancreatitis is uncommon in patients with preeclampsia or HELLP syndrome; the hemorrhagic form is uniquely

Martin, Rose, and Briery primarily related to gestational age at delivery and not to disease status.28,141-146 Similarly, earlier prematurity is responsible for the higher perinatal mortality recorded in eclamptic pregnancies with HELLP syndrome compared with non-HELLP eclampsia.20,25,147 Neonatal survival was 100% in the Mississippi experience if newborn weight was 600 g or greater and following a full course and time interval (48 hours) of antenatal corticosteroids for fetal lung maturation.148 Continuation of HELLP syndrome pregnancy beyond 26 weeks and the time necessary for steroid enhancement of fetal lung maturation increases the risk of stillbirth substantially.144,149 In the Mississippi series, stillbirth was almost tripled for class 1 or 2 compared with class 3 or non-HELLP severe preeclampsia,28 in part related to fetal growth restriction and placental abruption. Fetal growth restriction and abnormal Doppler velocimetry impact up to 39% and 48% of patients, respectively.22,130,150 Although neonatal thrombocytopenia occurs in a substantial percentage (up to 38%)130 of newborn infants, a higher incidence of intraventricular hemorrhage has not resulted.151,152 Longterm prognosis for the children of mothers with HELLP syndrome is comparable to controls matched for gestational age.152 Small-for-gestational-age neonates signicantly increase weight and length over the rst 4 years of life compared with matched controls.153 Newborn infants weighing less than 1250 g compared with birth weight-matched controls had signicantly less cerebral palsy and mental disability at 3 years of life.146

921 2 small randomized clinical trials (nonblinded, nonplacebo controlled) were undertaken in Jackson using intravenous (IV) high-dose dexamethasone versus no steroids during 1992 through 1993 in 65 patients with antepartum or postpartum HELLP syndrome.158,159 Stabilization and signicant improvement in laboratory and clinical parameters associated with HELLP syndrome occurred in women who received antenatal and/ or postpartum corticosteroids.158,159 Subsequent to the publication of these ndings, retrospective scrutiny of selected data present in several published series of patients with severe preeclampsia from the 1970s and 1980s revealed ndings consistent with this new observation that high-dose dexamethasone appeared to arrest the deterioration of laboratory parameters in patients fullling criteria for HELLP syndrome.16,139,160-162 Four other small randomized, controlled trials have been undertaken comparing the use of high-dose dexamethasone or prednisolone (50 mg twice daily) with either no treatment, placebo, or with betamethasone. Two HELLP trials were undertaken antepartum63,163 and 2 evaluated postpartum corticosteroid treatment.164,165 Signicantly improved biochemical parameters of HELLP syndrome and clinical parameters of mean arterial pressure and urinary output were consistently reported. In the most recently reported trial from The Netherlands,80 the prednisolone-treated group of 15 antepartum patients had a 50% reduction in HELLP syndrome exacerbations compared with 15 placebo-treated controls and a signicantly shorter time to normalize postpartum platelets. All 3 major maternal complications occurred in the placebo groupd formation of a liver hematoma in 2 patients and rupture of the liver in a third patient with maternal death. No signicant neonatal dierences between groups were noted in the immediate neonatal period or at infant follow-up.80 On the basis of the ndings from the rst 2 prospective clinical trials and the preceding case series ndings that led to the trials, interpreting them to collectively indicate a clear patient benet to treatment, practice guidelines at University Hospital in Jackson were revised in mid-1993 to routinely initiate IV high dose (10 mg IV every 12 hours) dexamethasone antepartum or postpartum for (1) any patient with class 1 or 2 HELLP syndrome and (2) any patient with class 3 HELLP syndrome associated with epigastric pain, eclampsia, severe hypertension, and/or any evidence of major organ system morbidity. Patients with uncomplicated class 3 disease were monitored and subsequently treated if they met either of the 2 criteria.21,27,166,167 The dosage of drug used is approximately double that recommended for fetal lung maturation purposes and half the amount used for adults with newly diagnosed immune thrombocytopenic purpura.168,169 Postpartum and approximately 12 hours after the last antepartum

The integral role of corticosteroids


The probability that HELLP syndrome is a SIRS-like inammatory form of severe preeclampsia50 leads to consideration of anti-inammatory/immunosuppressive agents for treatment, specically corticosteroids. The consistently favorable response of HELLP syndrome laboratory parameters to corticosteroids suggests the presence of an underlying corticosteroid-responsive step(s) in its pathogenesis and a therapeutic benet to their use. Corticosteroids may act by one or more mechanisms to alter endothelial activity/interaction with circulating cells including erythrocytes and platelets, impact translation/transcription, interrupt hepatocyte damage by placenta-derived CD95-L and/or to disrupt signaling for inammatory cytokine production by the endogenous immune system.154 A recent publication that thoroughly explores the pharmacology and physiology of corticosteroids relevant to pregnancy and HELLP syndrome is recommended to the interested reader for review.154 The potential therapeutic value of corticosteroids for patients with HELLP syndrome was rst recognized in the early 1990s by 2 groups of investigators, one in Denver155 and the other in Jackson, MS.156,157 The rst

922 dose, IV dexamethasone is given twice more at 10 mg IV every 12 hours and usually tapered with 2 lesser doses of 5 mg IV every 12 hours for a full course. The regimen is lengthened or shortened to t individual patient circumstances.167 Routine high-dose IV dexamethasone according to the Mississippi regimen is now in its twelth year of practice utilization in Jackson; historical control groups from the era before 1992 when corticosteroid trials began are the only potential comparison groups of patients. Compared with 246 patients with class 1 or 2 HELLP syndrome treated between 1985 and 1991 when only 16% received a complete or incomplete course of corticosteroids to enhance fetal lung maturation, significantly reduced composite maternal disease was observed in 228 patients managed between 1994 and 2000 with 90% aggressive corticosteroid utilization. There were signicantly improved laboratory parameters, less progression to class 1 HELLP syndrome, less frequent need for antihypertensive therapy, less requirement for transfusion, lower incidence of major maternal morbidity, and shortened postpartum recovery.170 Overall maternal morbidity rates of 64% for class 1 HELLP syndrome, 54% for class 2, and 40% for class 3 improved to 49%, 22%, and 21%, respectively, with an aggressive corticosteroid regimen compared with an 11% baseline for non-HELLP severe preeclampsia.25,27,28 Comparable quantitative and qualitative benets occurred in similarly treated patients with postpartum HELLP syndromeda more rapid normalization of platelet counts and LDH values and a clinically signicant reduction of indicated transfusion, need for intubation or intensive respiratory therapy, invasive hemodynamic monitoring, infectious- or bleeding-related morbidity, and length of postpartum hospital course.171 At least 7 other groups have also retrospectively reviewed case series and found that corticosteroids improve laboratory indices and positively impact HELLP syndrome severity and pathogenesis.172-178 Tompkins and Thiagarajah,173 for instance, interpret their data to show best benet using 2 doses of intramuscular (IM) betamethasone (12 mg each) given 12 hours apart rather than the National Institutes of Health (NIH)179 recommended interval of 24 hours. The ndings of OBrien et al175 point toward accelerated (shorter interval) standard dose fetal lung maturation steroids (either 12 mg betamethasone IM every 12 hours ! 2 or dexamethasone IV 6 mg every 6 hours), or a higher than Mississippi regimen of IV dexamethasone (10 mg every 6 hours ! 2, then 6 mg every 6 hours ! 2-4 doses) given to patients with antepartum HELLP syndrome to improve platelet counts, reduce liver enzyme abnormalities, and prolong latency to delivery in a dosedependent manner. In addition to these 13 publications, several other observations are oered that favor the routine inclusion

Martin, Rose, and Briery of aggressive corticosteroids for patients with HELLP syndrome:  Liver hemorrhage or rupture is rarely encountered in the undelivered pregnant patient with preeclampsia/ eclampsia who is receiving corticosteroids for fetal lung maturation or aggressive corticosteroids for treatment of HELLP syndrome.21,28  Liver complications may be particularly susceptible to interdiction with early aggressive corticosteroids, especially in the symptomatic class 3 HELLP syndrome patient with other underlying pathology.86 Pauzner et al86 noted recently that antiphospholipid syndrome was present in all 4 patients with hepatic infarction and HELLP syndrome (described as incomplete in 3 of 4 cases), and their literature survey noted that anticardiolipin antibodies and/or lupus anticoagulant were positive in 15 or 16 patients with hepatic complications for whom laboratory data were available. A similar series and a case report were published recently from France.90,91  Because renal and/or hepatic dysfunction with HELLP syndrome exhibit can be exhibited very early in disease development before class 1 or 2 criteria are met, it is possible that routine initiation of aggressive corticosteroids in class 3 and partial HELLP patients might prevent disease progression and signicant maternal hepatorenal morbidity.  When aggressive corticosteroids are not used, significant maternal morbidity180 or mortality can occur that might otherwise have been avoided. For instance, HELLP syndrome developing in association with severe systolic hypertension above 160 mm Hg may enhance the potential of cerebral blood vessels to bleed when corticosteroids are absent from management. Among a highly selected group of 28 women with preeclampsia-induced severe systolic hypertension who had cerebral hemorrhage and stroke, 18 (64%) had evidence for concurrent class 1, 2, or 3 HELLP syndrome before the cerebral catastrophe and no patient had been a recent corticosteroid recipient.181 None of 54 patients dying with HELLP syndrome in the Isler series received corticosteroids, many of whom had CNS pathology.138 Corticosteroids use was not described in 104 patients from France with a 79% complication rate in the class 1 HELLP category,106 or in recent series from Germany, China, and Turkey with high rates of maternal morbidity,130,182,183 and they were usually absent from the management of patients with signicant maternal morbidity reported before 1990.6-17  Aggressive corticosteroids can eect an increase in platelet count suciently to undertake regional anesthesia (from 0% to 42%) and to enable cervical ripening, induction of labor and vaginal delivery.184,185 Up to 75% of patients with HELLP

Martin, Rose, and Briery syndrome can become candidates for regional anesthesia after high-dose corticosteroid administration if a platelet threshold of 75,000/mL is deemed adequate, and a higher rate of vaginal delivery can be accomplished than would otherwise be possible especially in relatively preterm gestations.185 In the absence of corticosteroid use, the cesarean rate is high and vaginal delivery is a rare event.128,186  A recent prospective randomized clinical trial undertaken in the authors hospital found no clear treatment benet with postpartum high-dose dexamethasone for puerperal patients with non-HELLP severe preeclampsia at diagnosis.187 The only 2 patients to subsequently have postpartum HELLP syndrome develop were in the placebo group, and both responded quickly to the emergent initiation of IV dexamethasone after study assignment as placebo was ascertained.

923 long-term potentially adverse implications to the newborn infant remain a question.172,190-192 Lower birth weight, lower head circumference, neonatal adrenal suppression, and increased infection are theoretical risks to a newborn infant exposed to even a very short course of high-dose corticosteroids, but evidence for this is lacking. Potent glucocorticoids used for pregnancies with HELLP syndrome may actually impart a fetal advantage because placental vascular resistance by Doppler assessment appears to be reduced briey in singleton and multiple gestations after maternal betamethasone administration.193,194 In pregnant ewes receiving extended dexamethasone prenatally (20 days with 20 mg/kg maternal body weight), no evidence of altered renal function or predisposition to adult hypertension compared with controls was found.195

Summary
Despite current limitations in sample size and study structure, a consistent positive picture of patient benet emerges from a review of the present literature that we suspect will be shown denitively once large multicenter clinical trials are undertaken. This is consistent with our considerable bedside experience gained over many years and in a multitude of patient circumstances and situations that a routine practice of initiating aggressive corticosteroids early in HELLP syndrome pregnancies will prevent them from progressing along a continuum of worsening morbidity, a critically important concept for clinicians to embrace to reduce maternal mortality rates in patients with this disease.196 In view of the absence of a demonstrated downside to this approach either for the mother or the fetus, given the body of armative available literature, we believe it most benecial to patients now to be managed according to the recommendations that follow.

Choice of corticosteroid
Although approximately equivalent in potency, IV dexamethasone appears to be more eective than IM betamethasone, perhaps by delivering the drug directly into the vasculature of the aected organ systems.163,188 Preferences for other regimens by others were listed earlier. Sibai recommends an aggressive corticosteroid regimen similar in potency to the Mississippi protocol (dexamethasone 10 mg IV every 12 hours) for antepartum HELLP syndrome to improve maternal status, using 2 doses of either betamethasone 12 mg IM every 12 hours (instead of every 24 hours) or dexamethasone 12 mg IV (instead of 5 or 6 mg) every12 hours with delivery to be accomplished within 24 hours after the last dose of corticosteroids.22 Determination of preferred drug, dosage, and regimen specic to clinical circumstances awaits large multicenter studies.

Potential maternal-fetal risks


Potential maternal risks include rebound thrombocytopenia, adrenal suppression, infection, and the masking of potential complications or other disease processes. The available data are insucient to estimate if there are any adverse short- or long-term neonatal-infant eects from brief aggressive corticosteroids for HELLP syndrome. Neither dexamethasone or betamethasone is preferable from the fetal perspective in regard to short-term outcomes.189 The use of aggressive corticosteroids for antepartum HELLP syndrome is recommended exclusively as a short-term intervention; continuation of pregnancy after more than 48 hours of aggressive corticosteroid administration for very preterm HELLP syndrome pregnancy can lead to signicant maternal and fetal morbidity and mortality.149 Evidence is meager (few case reports) regarding corticosteroid prolongation for many days to weeks of a previable HELLP syndrome pregnancy to viability, and

Fundamentals of practicedThe application of aggressive corticosteroids


The fundamental management concepts for treatment of patients with HELLP syndrome using aggressive corticosteroids is presented in core concepts (Table VI) and as an algorhythm (Figures 2 and 3). Further considerations are discussed in paragraphs to follow. In any patient suspected of having HELLP syndrome, basic laboratory evaluation includes a complete blood count with platelets, serum AST, and total serum LDH. Extended assessment can include serum creatinine, glucose, bilirubin, coagulation studies, and a peripheral smear. Elevation of direct bilirubin and prolongation of coagulation studies out of proportion to mild thrombocytopenia occurs early in patients with AFLP but is unusual with HELLP syndrome unless the disease is very advanced (class 1).

924
Table VI Fundamental principles of HELLP syndrome management with aggressive corticosteroids

Martin, Rose, and Briery

 Laboratory testing to detect HELLP syndrome is recommended for any pregnant patient presenting with possible preeclampsia, especially pretermdearly detection is preferred.  Whether a patient presents with class 1, 2, or 3 HELLP syndrome or has complete/incomplete disease parameters does not lessen the clinicians pressing need to undertake appropriate evaluation and intervention for the patient.  HELLP syndrome is a systemic and progressive pregnancy disease process that usually shows signs of recovery only after delivery is accomplished. The rst priority is to assess the maternal-fetal condition and to determine secondarily whether delivery is immediately indicated or can be delayed while aggressive corticosteroids are used to accelerate fetal lung maturation, enhance maternal status, and optimize conditions either for vaginal or abdominal delivery to occur.  Aggressive corticosteroids clearly benet the mother with HELLP syndrome according to stage of disease when drug therapy is initiated, agent used, amount and route of administration.  A proactive, preventative early aggressive application of corticosteroids for the patient with antepartum or postpartum HELLP syndrome probably realizes the greatest maternal benet regardless of gestational age (Figures 2 and 3).  The patient with HELLP has severe preeclampsia and is managed accordingly with intensive surveillance and care during the peripartum interval, including magnesium sulfate and aggressive antihypertensive therapy to minimize systolic blood pressures above 160 mm Hg.22,170  The CNS is the most commonly affected system in mothers dying from HELLP syndromedthe aggressive use corticosteroids and antihypertensives probably lessens the risks of stroke and death. Early aggressive corticosteroids may also lessen hepatorenal morbidity.  Aggressive corticosteroids in patients with HELLP syndrome increases the providers chance to provide regional anesthesia during labor and delivery and to maximize the potential for vaginal delivery.  Early transfer of the patient with HELLP syndrome to a suitable facility that can provide 24-h intensive care and consultation for maternal-fetal-neonatal needs should be considered if appropriate.  Perinatal outcome is predominantly gestational age-dependent. Because stillbirth and placental abruption occur with increased frequency in relation to impaired fetal growth and maternal disease severity, efforts to prolong HELLP syndrome pregnancy more than 48-72 h (regardless of gestational age) are undertaken at some risk to mother and child.  The clinician must be mindful that the patient considered to have HELLP syndrome may have some other disorder, especially AFLP that is relatively uncommon but has a much worse prognosis.

An aggressive corticosteroid regimen is initiated as soon as the diagnosis of class 1 or 2 HELLP syndrome is made or if the patient has complicated class 3 HELLP syndrome. Continuation during cervical ripening and induction of labor can be used to facilitate attempted vaginal delivery or to improve the mothers hematologic status before abdominal delivery. If the fetus is preterm and previable such that cesarean delivery is not a fetal consideration, presence or absence of fetal heart tones is assessed intermittently to determine whether a neonatal team should be summoned at delivery to assess the reasonableness of resuscitation eorts. Rarely a pregnancy with borderline viability has been prolonged with aggressive corticosteroids but this is not usually recommended.190-192,197,198 It is particularly discouraged in a patient with a fetal abnormality or major maternal morbidity such as renal failure.199 HELLP syndrome detected before fetal viability may identify a pregnancy complicated by partial mole/triploidy,200 trisomy 13,201 antiphospholipid syndrome,87 autoantibodies to angiotensin AT(1)-receptor,202 or severe preterm preeclampsia with mirror syndrome.203 Maternal-fetal status, gestational age, presence of labor, cervical Bishop score, prior maternal obstetric history, and response to aggressive corticosteroids all impact management of the patient with a preterm viable fetus and HELLP syndrome. Immediate cesarean

delivery is not generally indicated or recommended; vaginal or cesarean delivery after 24 to 48 hours of corticosteroids are better options to achieve maximal maternal and fetal benet.204 Vaginal delivery rates of 32% for gestations less than 30 weeks, 61% at 30 to 31 weeks, and 62% at 32 to 33 weeks (overall induction success 145/247 or 59%, 37% !28 weeks) can be achieved.186 Nevertheless, because vaginal delivery rates with HELLP syndrome are below 50% for gestations less than 30 weeks, Sibai22 advocates elective cesarean delivery for all women diagnosed with HELLP syndrome at a gestation age less than 30 weeks when spontaneous labor is not present and the Bishop score is less than 5. A patient with a low Bishop score in association with fetal growth restriction and/or oligohydramnios may not be a good candidate for trial of labor. Otherwise, vaginal delivery is attempted in patients in active labor less than 30 weeks with ruptured membranes or with a Bishop score 5 or more in the absence of obstetric contraindications. Once the 30-week gestational age threshold is reached, an attempt at vaginal delivery is usually recommended while aggressive corticosteroids are initiated. Epidural or spinal anesthesia is the preferred anesthetic for patients with preeclampsia.205 Approximately 50% of patients with HELLP syndrome can be candidates for regional anesthesia during a trial of labor using

Martin, Rose, and Briery

925

Figure 2

HELLP management algorithm: aggressive corticosteroids.

a threshold of 100,000/mL platelets.187 In these circumstances, the decision of abdominal versus vaginal delivery becomes more of an obstetric issue rather than a response to a rapidly worsening maternal-fetal condition. Furthermore, patients who receive regional anesthesia avoid the greater risks associated with general anesthesia. When motivated, providers can depend on corticosteroids to improve maternal platelet counts suciently to increase the epidural rate for patients with HELLP syndrome from 0% to 57%.184 When cesarean delivery without trial of labor is planned, waiting approximately 6 hours after beginning an aggressive corticosteroid regimen is recommended to stabilize the disease process, improve laboratory parameters, enable institution of regional anesthesia, and reduce the need for platelet or red cell transfusion. Given the absence of neurologic or hematologic complications with regional anesthesia in HELLP syndrome patients managed in Panama without corticosteroids or platelet count restrictions, the likelihood of bleeding complications with regional anesthesia is small.205 Aggressive corticosteroid administration is associated with a signicant decrease in the required use of blood products21 and consequently a secondary decrease in infectious morbidity. When emergent cesarean delivery must proceed without waiting for a steroid eect and/ or in the rare patient with advanced disease and a

platelet count less than 40,000/mL that is unresponsive to corticosteroid use, platelet transfusion of 6 to 10 units of platelets is recommended immediately prior to intubation.206 Prevention of severe systolic hypertension (O160 mm Hg) is paramount; recommendations to maintain systolic pressures under 155 mm Hg and diastolic pressures under 105 mm Hg are reasonable goals.22,181 Labetolol, hydralazine, or nifedipine are the preferred agents for treatment of acute hypertension in this setting with infused dilute nitroglycerin held in reserve.207 There have been no randomized trials of cesarean operative technique for patients with HELLP syndrome. Delayed skin closure or type of skin incision do not appear to inuence the frequency of wound complications.208 In the absence of postpartum aggressive corticosteroids, a high incidence of hematoma formation can occur despite placement of a subfascial drain and keeping the skin incision open for 48 hours.22 Most of the fundamental principles of management for patients with antepartum HELLP syndrome apply equally to postpartum/postoperative patients. Newonset postpartum disease appears usually within the rst days after delivery and is treated with aggressive corticosteroids similar to antepartum disease.21,170,171 The treatment is tailored to the patient; corticosteroid dosage is reduced once an upward trend in platelets and

926

Martin, Rose, and Briery

Figure 3

Class 3 or incomplete/partial HELLP syndrome.

a downward trend in total serum LDH is recorded, and discontinued with normalization of HELLP laboratory parameters and resolution of signs and symptoms of preeclampsia. Signicant renal injury is infrequently encountered in patients with HELLP syndrome unless placental abruption or a major hemorrhage also occurs.209 Most often renal dysfunction responds to measures short of dialysis or only a brief course of dialysis.19,209,210 Because a convincing renal benet to aggressive corticosteroids has not been demonstrated, the basic patient management principles for patients with acute renal failure are used.211 Almost all instances of spontaneous subcapsular hematomas or hepatic rupture in pregnancy occur in association with HELLP syndrome.212-214 As thrombocytopenia worsens into the lowest ranges (class 1), in conjunction with the onset of sudden epigastric pain, the likelihood of nding abnormal hepatic imaging with computed tomography or magnetic resonance imaging increases. For reasons given earlier, we speculate that it benets patient care to immediately begin aggressive corticosteroids for any patient with suspected HELLP syndrome and having hepatic injury develop,

regardless of disease class. Several excellent treatises have been published recently that review the management of HELLP-related hepatic complications such as hepatic rupture.129,212-217

Beyond corticosteroids
Plasma exchange or plasma infusion have been used sparingly for recalcitrant and/or complicated HELLP syndrome that is unresponsive to standard therapy.83,218-224 Some of the postulated mechanism of actions include (1) clearance from the circulation of debris, toxins, antigen-antibody complexes, damaged red cell components or other substances that may be compromising normal coagulation and organ function; and (2) replacement of uid, clotting factors, proteins, and other plasma components that are required to achieve homeostasis and healing. Prevention of intravascular uid overload is enhanced versus straight transfusion, particularly in the patient with compromised renal function. Collaborative care with intensivists and hematologist/transfusion medicine subspecialists is imperative. Because patients in these circumstances are rare, unique, and dicult to accurately quantify, randomized

Martin, Rose, and Briery clinical trials are unlikely to be undertaken or even feasible. Thus, the role of plasma exchange in HELLP syndrome management remains controversial but less frequently a concern we speculate because of early diagnosis and aggressive corticosteroids. There is little evidence suggesting ecacy to the use of heparin,178,225 activated factor VII,226 or haptoglobin227 for treatment of HELLP syndrome. Attempted prolongation of pregnancy with hydration and antihypertensives is not recommended because it is associated with increased maternal and perinatal morbidity related to placental abruption and hepatic rupture.80,228

927 (!32 weeks).234 To date, anything other than close monitoring of subsequent pregnancies for problems of prematurity and preeclampsia (preterm labor, bleeding, fetal growth restriction) has not been superceded by specic testing or augmented by eective preventative measures. Testing for LCHAD mutation (long-chain 3-hydroxyacyl coenzyme A dehydrogenase deciency) is rarely positive in patients with HELLP syndrome in contrast to the situation with AFLP235-237 and therefore not recommended.238

Challenges and conclusions


An expanded, more inclusive disease classication system for HELLP syndrome is needed particularly if the potential for early aggressive corticosteroids to avert most signicant maternal morbidity is to be studied adequately in appropriately structured, large multicenter clinical trials. Some form of a composite maternal morbidity index also is needed to better describe the spectrum of systemic morbidity potentially experienced by mothers with this condition. As expected with a disease process with variable rates of progression, different stages at initial presentation, alteration by various interventions, and characterization by inconsistent and variable laboratory methodologies, there has been a lack of consensus among researchers and confusion among clinicians. The issue of standardization of diagnosis and disease classication is an important goal, so that research ndings are comparable and recommended clinical managements can become progressively more evidence based. We believe that the scientic community is on the threshold of a much better understanding of the pathogenesis of HELLP syndrome specically and preeclampsia-eclampsia in general. Knowledge of the ndings related to the pathogenesis and pathophysiology of this disorder and the ameliorating eect of corticosteroids on the disease process is foundational to understanding the challenges of diagnosis, classication, and management. A patient can present initially anywhere along the spectrum of disease development, and disease expression is inuenced by whether corticosteroids have been given for any reason. Thus, the accurate interpretation of any publication about HELLP syndrome requires a clear description of when in the development of HELLP syndrome laboratory or research testing was performed to study its pathogenesis or make its clinical diagnosis, including a statement of the presence or absence of corticosteroids during patient management ideally noting at what stage in disease these agents and dosages were given to the patient. Large-scale multicenter trials investigating various corticosteroid regimens for patients with this spectrum of HELLP syndrome conditions are desirable (including various types that cross or do not cross into the fetal circulation63), with

Prognosis: Recovery
Patients with HELLP syndrome usually recover completely, although relapses can occur in the absence of corticosteroid administration.224 After-eects of disease can persist for extended periods if hepatic or renal damage has occurred.229 Long-term follow-up of mothers and children from HELLP syndrome pregnancies are few in number. Renal function was not permanently impaired in 23 women with acute renal failure and HELLP syndrome who were monitored an average of 4.6 years; 8 patients had 11 subsequent pregnancies, 9 of which were term gestations.230 Similar normalization of renal function after a HELLP syndrome pregnancy was reported by Jacquemyns Belgian group,229 but higher systolic and diastolic blood pressures were observed at 5 years compared with controls. In Amsterdam, the incidence of subsequent hypertension requiring treatment was 3 times higher than controls.230 In the absence of acute renal failure, there was no detectable impairment of renal function at least 5 years after HELLP syndrome in 10 patients. Stroke in patients with HELLP syndrome left residual defects in 10 of 13 patients (77%) who survived the acute insult.181 No permanent adverse eects on liver function have been reported. Emotional trauma, both immediate and delayed, can be a signicant patient issue.231,232

Patient counseling: Future pregnancy


Women with a prior history of HELLP syndrome carry an increased risk of at least 20% (range 16%-52%) that some form of gestational hypertension will recur in a subsequent gestation. The rate of recurrent HELLP syndrome itself varies between 2% and 19% depending on the population studied, gestational age at onset, whether there is concurrent vascular disease of any type, and very likely the unique genetic prole of the individual patient, her partner, and her progeny.233,234 In the Mississippi study with a 75% African-American prole, the recurrence risk was 42% to 43% for any type of preeclampsia-eclampsia, but this increased to 61% if the preceding aected pregnancy was very preterm

928 particular attention to dene benets and limitations according to the stage and circumstances in which therapy is initiated. Risk factors for severe renal and hepatic complications of HELLP syndrome require further investigation with regard to concurrent predisposing conditions such as antiphospholipid syndrome. Although short-term utilization of corticosteroids as currently used has not been shown to negatively impact the fetus or neonate, surveillance for possible adverse eects should continue. We believe that widespread dissemination of the information presented herein to practicing cliniciansdbetter recognition through cognition and a management scheme focused on early aggressive corticosteroid administrationdis needed now to minimize maternal-perinatal morbidity and mortality with this condition while more extensive study continues.

Martin, Rose, and Briery


17. Goodlin RC, Cotton DB, Haesslein HC. Severe EPH gestosis. Am J Obstet Gynecol 1978;132:595-8. 18. Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 1982;142:159-67. 19. Abraham KA, Connolly G, Farrell J, Walshe JJ. The HELLP syndrome, a prospective study. Ren Fail 2001;23:705-13. 20. Vigil-De Gracia P. Pregnancy complicated by pre-eclampsiaeclampsia with HELLP syndrome. Int J Gynecol Obstet 2001;72: 17-23. 21. Martin JN Jr, Magann EF, Isler CM. HELLP Syndrome: the scope of disease and treatment. In: Belfort MA, Thornton S, Saade GR, editors. Hypertension in pregnancy. Chap 7. Oxford: Marcel Dekker; 2003. p. 141-88. 22. Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes and low platelet count. Obstet Gynecol 2004;103:981-91. 23. Barton JR, Sibai BM. Diagnosis and management of hemolysis, elevated liver enzymes and low platelets syndrome. Clinical Perinatol 2004;31:807-33. 24. Baxter JK, Weinstein L. HELLP syndrome: the state of the art. Obstet Gynecol Surv 2004;59:838-45. 25. Martin JN Jr, Magan EF, Blake PG. Analysis of 454 pregnancies with severe preeclampsia/eclampsia/HELLP syndrome using the 3-class system of classication. Am J Obstet Gynecol 1993; 168:386. 26. Sibai BM, Ramadan MK, Usta I, Salama M, Mercer BM, Friedman SA. Maternal morbidity and mortality in 442 pregnancies with HELLP syndrome. Am J Obstet Gynecol 1993;169:1000-6. 27. Martin JN Jr, Magann EF. HELLP syndrome: current principles and recommended practices. Curr Obstet Med 1996;4:129-75. 28. Martin JN Jr, Rinehart K, May WL, Magann EF, Terrone DA, Blake PG. The spectrum of severe preeclampsia: comparative analysis by HELLP syndrome classication. Am J Obstet Gynecol 1999;180:1373-84. 29. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989;161:1200-4. 30. Roberts JM. Objective evidence of endothelial dysfunction in preeclampsia. Am J Kidney Dis 1999;33:992-7. 31. Friedman SA, Taylor RN, Roberts JM. Pathophysiology of preeclampsia. Clin Perinatol 1991;18:661-82. 32. Lindheimer M, Cunningham FG. Hypertension in pregnancy. N Engl J Med 1992;326:927-32. 33. Zeeman GG, Dekker GA, van Geijn HP, Kraayenbrink AA. Endothelial function in normal and preeclamptic pregnancies: a hypothesis. Eur J Obstet Gynecol Reprod Biol 1992;43:113-22. 34. Roberts JM, Redman CWG. Preeclampsia: more than pregnancyinduced hypertension. Lancet 1993;341:1447-54. 35. Stratta P, Canavese C, Vercellone A. HELLP, microangiopathic hemolytic anemia, and preeclampsia. Hypertens Pregnancy 1993; 12:487-96. 36. Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension 2005;46:1243-9. 37. Martin JN Jr, Blake PG, Perry KG, McCaul JF, Hess LW, Martin RW. The natural history of HELLP syndrome: patterns of disease progression and regression. Am J Obstet Gynecol 1991;164:1500-13. 38. Martin JN Jr, Blake PG, Lowery SL, Perry KG, Files JC, Morrison JC. Pregnancy complicated by preeclampsia-eclampsia with HELLP syndrome: how rapid is postpartum recovery? Obstet Gynecol 1990;76:737-41. 39. Katz VL, Thorp JM Jr, Rozas L, Bowes WA Jr. The natural history of thrombocytopenia associated with preeclampsia. Am J Obstet Gynecol 1990;163:1142-3. 40. Neiger R, Contag SA, Coustan DR. The resolution of preeclampsiarelated thrombocytopenia. Obstet Gynecol 1991;77:692-5.

References
1. Schmorl G. Pathologisch-anatomische Untersuchungen uber Puerperal-Eklampsie. Leipzig: FCW Vogel; 1893. 2. Dienst A. Experimentaelle Studien uber die Aetiologische Bedeutung des Fibrinsferments und Fibrinogens fur die Schwangerschaftsniere und die Eklampsie. Arch Gynaekol 1912;96:43-170. 3. Denecke G. Blut and lymphe. In: Hinselman H, editor. Die Eklampsie. Bonn: Cohen; 1924. p. 293-360. 4. Chesley LC. Disseminated intravascular coagulation. In: Chesley LC, editor. Chesleys hypertensive disorders in pregnancy. New York: Appleton-Century-Crofts; 1978. p. 88-118. 5. Dieckmann WJ. Toxemias of pregnancy, 3rd ed. St Louis: Mosby; 1952. p. 362-9. 6. Pritchard JA, Weisman R Jr, Ratno OD, Vosburgh GJ. Intravascular hemolysis, thrombocytopenia and other hematologic abnormalities associated with severe toxemia of pregnancy. N Engl J Med 1954;250:89-98. 7. Pritchard JA, Cunningham FG, Mason RA. Coagulation changes in eclampsia: their frequency and pathogenesis. Am J Obstet Gynecol 1976;124:855-64. 8. Brain MC, Kuah K-B, Dixon HG. Heparin treatment of haemolysis and thrombocytopenia in pre-eclampsia. J Obstet Gynaecol Br Commonw 1967;74:702-11. 9. Scott R, Gordon S, Schatz A, Casella S. Acute hemolysis and thrombocytopenia in eclampsia. Obstet Gynecol 1970;36:128-31. 10. McKay DG. Hematologic evidence of disseminated intravascular coagulation in eclampsia. Obstet Gynecol Surv 1972;27: 399-407. 11. Kitzmiller JL, Lang JF, Yellenosky PF, Lucas WE. Hematologic assays in pre-eclampsia. Am J Obstet Gynecol 1974;118:362-7. 12. Vardi J, Fields GA. Microangiopathic hemolytic anemia in severe pre-eclampsia. Am J Obstet Gynecol 1974;119:617-22. 13. Killam AP, Dillard SH Jr, Patton RC, Pederson PR. Pregnancyinduced hypertension complicated by acute liver disease and disseminated intravascular coagulation. Am J Obstet Gynecol 1975;123:823-8. 14. Lopez-Llera M, de la Luz Espinosa M, Diaz de Leon M, Linares GR. Abnormal coagulation and brinolysis in eclampsia: a clinical and laboratory correlation study. Am J Obstet Gynecol 1976; 128:681-92. 15. Schwartz ML, Brenner WE. The obfuscation of eclampsia by thrombotic thrombocytopenic purpura. Am J Obstet Gynecol 1978;131:18-24. 16. Goodlin RC. Severe pre-eclampsia: another great imitator. Am J Obstet Gynecol 1976;126:855-64.

Martin, Rose, and Briery


41. Figini E, Za G, Squarcina M, Marras M, Passamonti U, Bocchino G, et al. Course and regression of HELLP syndrome. Minerva Ginecol 1996;48:405-8. 42. Makkonen N, Harju M, Kirkinen P. Postpartum recovery after severe preeclampsia and HELLP syndrome. J Perinat Med 1996; 24:641-9. 43. Rychel V, Williams KP. Correlation of platelet count changes with liver cell destruction in HELLP syndrome. Hypertens Pregnancy 2003;22:57-61. 44. Faridi A, Rath W. Dierential HELLP syndrome diagnosis. Z Gerburtschilfe 1996;200:88-95. 45. Strand S, Strand D, Seufert R, Mann A, Lotz J, Blessing M, et al. Placenta-derived CD95 ligand causes liver damage in HELLP syndrome. Gastroenterology 2004;126:849-58. 46. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, et al. Fas ligand in human serum. Nat Med 1996;2:317-22. 47. Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanish Y, Kashahara A, et al. Immunohistochemical detection of fas antigen in liver tissue of patient with chronic hepatitis C. Hepatology 1994;19:1354-9. 48. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996;125:680-7. 49. Balderas-Pena LM, Canales-Munoz JL, Angulo-Vazqule J, Anaya-Prado R, Gonzalez Ojeda A. The HELLP syndrome: evidence of a possible systemic inammatory response in preeclampsia? Ginecol Obstet Mex 2002;70:328-37. 50. Redman CWG, Sargent IL. Preeclampsia and the systemic inammatory response. Semin Nephrol 2004;24:565-70. 51. Harirah H, Donia SE, Hsu C-D. Serum Soluble FAS in HELLP Syndrome. Obstet Gynecol 2001;98:295-8. 52. Halim A, Kanayama N, El Maradny E, Maehara K, Takahaski A, Nosaka K, et al. Immunohistological study in cases of HELLP syndrome and acute fatty liver of pregnancy. Gynecol Obstet Invest 1996;41:106-12. 53. Terrone DA, Rinehart BK, May WL, Moore A, Magann EF, Martin JN Jr. Leukocytosis is proportional to HELLP syndrome severity: evidence for an inammatory form of preeclampsia. South Med J 2000;93:768-71. 54. Haeger M, Unander AM, Bengtsson A. Enhanced anaphylatoxin and terminal C5b-9 complement formation in patients with HELLP syndrome. Obstet Gynecol 1990;76:698-702. 55. Zusterzeel PLM, Wanten GJA, Peters WHM, Merkus HMWM, Steegers EAP. Neutrophil oxygen radical production in preeclampsia with HELLP syndrome. Eur J Obstet Gynecol 2001;99: 213-8. 56. Riordan SM, Williams R. Acute liver failure: targeted articial and hepatocyte-based support of liver regeneration and reversal of multiorgan failure. J Hepatol 2000;32:63-76. 57. Visser W, Beckmann I, Bremer HA, LIIM HL, Wallenburg HC. Bioactive tumour necrosis factor in preeclampsic patients with and without the HELLP syndrome. BJOG 1994;101:1081-2. 58. Cunningham DS, Christie TL, Evans EE, McCaul JF. Eect of the HELLP syndrome on maternal immune function. J Reprod Med 1993;38:459-64. 59. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia with HELLP syndrome. Am J Pathol 2002; 160:1405-23. 60. Sgambati E, Marini M, Thyrion GDZ, Parretti E, Mello G, Orlando C, et al. VEGF expression in the placenta from opregnancies complicated by hypertensive disorders. BJOG 2004;111: 564-70. 61. Maynard SE, Min J-Y, Merchan J, Lim K-H, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase

929
1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111: 649-58. Bussen S, Rieger L, Sutterlin M, Dietl J. Plasma VEGF levels are increased in women with severe preeclampsia or HELLP syndrome. Z Geburtshilfe Neonatol 2003;207:101-6. Schlembach D, Beinder E. Measurement of microcirculation in normal pregnancy, preeclampsia and HELLP syndrome [abstract]. Hypertens Pregnancy 2000;19(Suppl 1):114. Knerr I, Dachert C, Beinder E, Metzler M, Dotsch J, Repp R, et al. Adenomedullin, calcitonin gene-related peptide and their receptors: evidence for a decreased placental mRNA content in preeclampsia and HELLP syndrome. Eur J Obstet Gynecol 2002; 101:47-53. Groten T, Kreienberg R, Fialka I, Huber L, Wedlich D. Altered subcellular distribution of cadherin-5 in endothelial cells caused by the serum of preeclamptic patients. Mol Hum Reprod 2000; 6:1027-32. Diedrich F, Renner A, Rath W, Kuhn W, Wieland E. Lipid hydroperoxides and free radical scavenging enzyme activities in preeclampsia and HELLP syndrome: no evidence for circulating primary products of lipid peroxidation. Am J Obstet Gynecol 2001;185:166-72. Knapen MFCM, Mulder TPJ, Van Rooij IALM, Peters WHM, Steegers EAP. Low whole blood glutathione levels in pregnancies complicated by preeclampsia or the hemolysis, elevated liver enzymes, low plaelets syndrome. Obstet Gynecol 1998;92:1012-5. Raijmakers MTM, Roes EM, te Morsche RHM, Steegers EAP, Peters WHM. Haptoglobin and its association with the HELLP syndrome. J Med Genetics 2003;40:214-6. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347:589-900. Lattuada A, Rossi E, Calzarossa C, Candol R, Mannucci PM. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haemotologica 2003;88:1029-34. Benedetto C, Marozio L, Salton L, Maula V, Chieppa G, Massobrio M. Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome. Acta Obstet Gynecol Scand 2002;81: 1095-100. Bozzo M, Carpani G, Leo L, Marcozzi S, Sacchi E, Morono G, et al. HELLP syndrome and factor V Leiden. Eur J Obstet Gynecol Reprod Biol 2001;95:55-8. Van Pampus MG, Folf H, Koopman MM, van den Ende A, Butler HR, Reitsma PH. Prothrombin 20210G: a mutation and Factor V Leiden mutation in women with a history of severe preeclampsia and HELLP syndrome. Hypertens Pregnancy 2001;20:291-8. Schlembach D, Beinder E, Zingsem J, Wunsiedler U, Beckmann MW, Fischer T. Association of maternal and/or fetal factor V Leiden and G20210A prothrombin mutation with HELLP syndrome and intrauterine growth restriction. Clin Sci 2003;105: 279-85. Queyrel V, Ducloy-Bouthors AS, Michon-Pasturel U, Hachulla E, Dubuequoi S, Caron C, et al. Antiphospholipid antibodies in HELLP syndrome: clinical and biological study in 68 women. Rev Med Interne 2003;24:158-64. Samuels P. Disseminated intravascular coagulopathy and thrombocytopenia complicating pregnancy: an acute care approach. In: Foley MR, Strong TH Jr, Garite TJ, editors. Obstetric intensive care manual. 2nd ed. New York: McGraw-Hill; 2004. Steegers EAP, Mulder TPJ, Bisseling JGA, Delemarre FMC, Peters WHM. Glutathione S-transferase alpha as marker for hepatocellular damage in pre-eclampsia and HELLP syndrome. Lancet 1995;345:1571-2. Sibai BM, Taslimi MM, el-Nazer A, Amon E, Mabie BC, Ryan GM. Maternal-perinatal outcome associated with the

62.

63.

64.

65.

66.

67.

68.

69. 70.

71.

72.

73.

74.

75.

76.

77.

78.

930
syndrome of hemolysis, elevated liver enzymes and low platelets in severe preeclampsia-eclampsia. Am J Obstet Gynecol 1986; 155:501-9. Audibert F, Friedman SA, Frangieh AY, Sibai BM. Clinical utility of strict diagnostic criteria for the HELLP syndrome. Am J Obstet Gynecol 1996;175:460-4. van Runnard Heimel PH, Juisjes AJM, Franx A, Koopman C, Bots ML, Bruinse HW. A randomized placebo-controlled trial of prolonged prednisolone administration to patients with HELLP synrome remote from term: maternal and neonatal complications. Am J Obstet Gynecol 2004;191:S41. Vigil-DeGracia P. Acute fatty liver and HELLP syndrome: two distinct pregnancy disorders. Int J Gynaecol Obstet 2001;73: 215-20. Matsuda M, Mitsuhashi S, Watarai M, Yamamoto K, Hashimoto T, Ikeda S. HELLP syndrome associated with systemic lupus erythematosis. Intern Med 2003;42:1052-3. Roberts G, Gordon MM, Porter D, Jardine AG, Gibson IW. Acute renal failure complicating HELLP syndrome, SLE and antiphospholipid syndrome: successful outcome using plasma exchange therapy. Lupus 2003;12:251-7. Sullivan CA, Martin JN Jr, editors. Thrombotic microangiopathies in critical care obstetrics. 4th ed. Oxford: Blackwell Publishing; 2003. p. 408-19. Pitton MA, Petolillo M, Papi S, Grismondi GL, Masin GP, Forcelline F. Hemolytic uremic syndrome in twin pregnancy at 32 weeks with HELLP syndrome: a case report. Minerva Ginecol 2001;53:279-81. Pauzner R, Dulitzky M, Carp H, Mayan H, Kenett R, Farfel Z, Many A. Hepatic infarctions during pregnancy are associated with the antiphospholipid syndrome and in addition with complete or incomplete HELLP syndrome. J Thromb Haemost 2003;1:1758-63. Haram K, Trovik J, Sandset PM, Hordnes K. Severe HELLP syndrome in the 18th week of pregnancy associated with the antiphospholipid-antibody syndrome. Acta Obstet Gynecol Scant 2003;82:679-80. Sinha J, Chowdhry I, Sedan S, Barland P. Bone marrow necrosis and refractory HELLP syndrome in a patient with catastrophic antiphospholipid antibody syndrome. J Rheumatol 2002;29:195-7. Veres K, Papp K, Lakos G, Szomjak E, Szegedi G, Soltesz P. Primary antiphospholipid syndrome associated with HELLP syndrome in pregnancy. Orv Hetil 2003;144:1353-6. Thuong DLT, Tieulie N, Costedoat N, Andreu M-R, Wechsler B, Vauthier-Brouzes D, et al. The HELLP syndrome in the antophospholipid syndrome: retrospective study of 16 cases in 15 women. Ann Rheum Dis 2005;64:273-8. Koenig M, Roy M, Baccot S, Cuilleron M, de Filippis J-P, Cathebras P. Thrombotic microangiopathy with liver, gut, and bone infarction (catastrophic antiphospholipid syndrome) associated with HELLP syndrome. Clin Rheum 2005;24:166-8. Gupta RS, Rajaram S, Goel N, Singh KC. Severe folate deciency mimicking HELLP syndromedreport of two cases. J Indian Med Assoc 2003;101:32-4. Ohkuchi A, Minakami H, Suzuki I, Ayustawati Izumi A, Sato I. Liver dysfunction in pregnancy: CMV-induced hepatitis or HELLP syndrome? J Obstet Gynaecol Res 2001;27:319-23. Higgins SP, McMahan LP, Brennecks SP. Paroxysmal nocturnal haemoglobinuria in pregnancydnot to be confused with preeclampsia or HELLP syndrome: case report and literature review. J Obstet Gynaecol 2004;24:83-5. Akerbook-Straberger BM, Lotgering FK. Embryonal sarcoma of the liver in pregnancy associated with HELLP syndrome. Am J Obstet Gynecol 2004;190:556-7. Sardo ADS, Taylor A, Pellicano M, Romano L, Acunzo G, Bifulco G, et al. Myasthenia and HELLP syndrome. Eur J Obstet Gynecol Reprod Biol 2004;116:108-11.

Martin, Rose, and Briery


97. Lurie S, Sadan O, Glezerman M, Ezri T. Psuedocholinesterase deciency associated with HELLP syndrome. Am J Perinatol 2004;21:315-7. 98. Martin JN Jr, Stedman C. Imitators of preeclampsia and HELLP syndrome. Obstet Gynecol Clin North Am 1991;18:181-98. 99. Goodlin RC. Preeclampsia is the great imposter. Am J Obstet Gynecol 1991;164:1577-80. 100. Sibai BM. Imitators of severe preeclampsia/eclampsia. Clin Perinatol 2004;31:835-52. 101. Goodlin RC. Expanded toxemia syndrome or gestosis. Am J Obstet Gynecol 1986;154:1227-33. 102. Martin JN Jr, May WL, Magann EF, Terrone DA, Rinehart BK, Blake PG. Early risk assessment of severe preeclampsia: admission batter of symptoms and laboratory tests to predict likelihood of subsequent signicant maternal morbidity. Am J Obstet Gynecol 1999;180:1407-14. 103. Carpani G, Bozzo M, Ferrazzi E, DAmato B, Pizzotti D, Radaelli T, et al. The evaluation of maternal parameters at diagnosis may predict HELLP syndrome severity. J Matern Fetal Neonatal Med 2003;13:147-51. 104. Haddad B, Barton JR, Livingston JC, Chahine R, Sibai BM. Risk factors for adverse maternal outcome among women with HELLP syndrome. Am J Obstet Gynecol 2000;183:444-8. 105. Rinehart BK, Terrone DA, May WL, Magann EF, Isler CM, Martin JN Jr. Change in platelet count predicts eventual maternal outcome with HELLP syndrome. J Matern Fetal Med 2001;10:28-34. 106. Roussillon E, Estrade JP, Guyon F, Ekouevi D, Guillaume V, Horovitz J. Importance of thrombocytopenia for the management of HELLP syndrome: a report of 104 cases. J Gynecol Obstet Biol Reprod (Paris) 2003;32:541-8. 107. Catanzarite VA, Steinberg SM, Mosley CA, Landers CF, Cousins LM, Schneider JM. Severe preeclampsia with fulminant and extreme elevation of aspartate aminotransferase and lactate dehydrogenase levels: high risk for maternal death. Am J Perinatol 1995;12:310-3. 108. Sibai BM. The HELLP syndrome: much ado about nothing? Am J Obstet Gynecol 1990;162:311-6. 109. Terrone DA, Isler CM, May WL, Magann EF, Norman PF, Martin JN JrCardiopulmonary morbidity as a complication of severe preeclampsia-HELLP syndrome. J Perinatol 2000;20:78-81. 110. Woods JB, Blake PG, Perry KG Jr, Magann EF, Martin RW, Martin JN Jr. Ascites: a portent of cardiopulmonary complications in the preeclampsic patient with HELLP syndrome. Obstet Gynecol 1992;80:87-91. 111. Soh Y, Yasuhi I, Nakayama D, Isimaru T. A case of postpartum cerebellar infection with HELLP syndrome. Gynecol Obstet Invest 2002;53:240-2. 112. Onrust S, Santema JG, Aarnoudse JG. Preeclampsia and the HELLP syndrome still cause maternal mortality in the Netherlands and other developed countries: can we reduce it? Eur J Obstet Gynecol Reprod Biol 1999;82:41-6. 113. Ezri T, Aboutleish E, Lee C, Evron S. Intracranial subdural hematooma following dural puncture in a parturient with HELLP syndrome. Can J Anaesth 2002;49:820-3. 114. Knopp U, Kehler U, Riskmann H, Arnold H, Gliemroth J. Cerebral haemodynamic pathologies in HELLP syndrome. Clin Neurol Neurosurg 2003;105:256-61. 115. Marano E, Scuteri N, Vacca G, Orece G. HELLP syndrome with reversible posterior leukoencephalopathy. Neurol Sci 2003; 24:82-4. 116. Takanami K, Hasegawa T, Miyamori T, Matsumoto T, Yoshimoto Y, Tidor TReversible posterior leukoencephalopathy syndrome accompanied by HELLP syndrome and eclampsia: a case report. No Shinkei Geka 2001;29:967-70. 117. Wenzel M, Lehnan H. A case of mild ocular manifestations in pregnancy-induced hypertension with HELLP syndrome. Acta Ophthalmol 1994;72:391-2.

79.

80.

81.

82.

83.

84.

85.

86.

87.

88.

89.

90.

91.

92.

93.

94.

95.

96.

Martin, Rose, and Briery


118. Bumke JP, Whyte I, Macewen CJ. Bilateral serous retinal detachments in the HELLP syndrome. Acta Ophthalmol 1989;67:322-4. 119. Le SR, Yarian DL, Mascuilli L, Green SN, Baldomero RE. Vitreous haemorrhage as a complication of HELLP syndrome. Br J Ophthalmol 1990;74:498. 120. Lavavi H, Neri A, Zoldan J, Segal J, Ovadia J. Preeclampsia HELLP syndrome and postictal cortical blindness. Acta Obstet Gynaecol Scand 1987;66:91-2. 121. Gupta LY, Mansour SE. Bilateral bullous retinal detachment as a complication of the HELLP syndrome. Can J Ophthalmol 1994; 29:242-5. 122. Sanchez Vicente JL, Ruiz Aragon J, Nanwani K, Sanchez Vicente P, Guitoe Linares JR, Diez Garretas C, et al. Retinal detachment in preeclampsia and HELLP syndrome. Arch Soc Esp Oftalmol 2003;78:335-8. 123. Tung CF, Peng YC, Chen GH, Chow WK, Yang DY, Hu WH. Hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome with acute cortical blindness. Zhonghua Yi Xue Zhi 2001;64(8):482-5. 124. Tara PN, Byrne H, Francis PJ, Shennan A. HELLP syndrome complicated by visual loss. J Obstet Gynaecol 2003;23:562-3. 125. Tranos PG, Wickremasinghe SS, Hundal KS, Foster PJ, Jagger J. Bilateral serous retinal detachment as a complication of HELLP syndrome. Eye 2002;16:491-2. 126. Soltes L, Schmalfuss IM, Bhatti MT. Cortical blindness due to reversible posterior leukoencephalopathy syndrome in a patient with thrombotic thrombocytopenic purpura and preeclampsia. Arch Ophthalmol 2004;122:1885-7. 127. Celik C, Gezgine K, Altintepe L, Tonbul HZ, Yaman ST, Akyruek C, et al. Results of pregnancies with HELLP syndrome. Ren Fail 2003;25:613-8. 128. Basavilvazo Rodriguez A, Pacheco Perez C, Lemus Rocha R, Martinez Perez JM, Martinez Martineez A, Hernandez-Valencia M. Maternal and perinatal surgical complications in low platelet count with HELLP syndrome and severe preeclampsia-eclampsia. Ginecol Obstet Mex 2003;71:379-86. 129. Wicke C, Pereira PL, Neeser E, Flesch I, Rodegerdts EA, Becker HD. Subcapsular liver hematoma in HELLP syndrome: Evaluation of diagnostic and therapeutic optionsda unicenter study. Am J Obstet Gynecol 2004;190:106-12. 130. Ertan AK, Wagner S, Hendrik HJ, Tanriverdi HA, Schmidt W. Clinical and biophysical aspects of HELLP syndrome. J Perinat Med 2002;30:483-9. 131. Martin JN Jr, Perry KG Jr, Miles JF, Blake PG, Magann EF, Roberts WE, et al. The interrelationship of eclampsia HELLP syndrome and prematurity: cofactors for signicant maternal and perinatal risk. BJOG 1993;100:1095-100. 132. Williams KP, Wilson S. The impact of parity on the incidence of HELLP syndrome and small for gestational age infants in hypertensive pregnant women. J Obstet Gynaecol Can 2002;24: 485-9. 133. Isler CM, Rinehart BK, Terrone DA, May WL, Magann EF, Martin JN Jr. The importance of parity to major maternal morbidity in the eclamptic mother with HELLP syndrome. Hypertens Pregnancy 2003;22:287-94. 134. Moldenhauer JS, OBrien JM, Barton JR, Sibai BM. Acute fatty liver of pregnancy associated with pancreatitis: a life-threatening complication. Am J Obstet Gynecol 2004;190:502-5. 135. Yamanaka Y, Takeuchi K, Konda E, Samoto T, Satou A, Mizudori M, et al. Transient postpartum diabetes insipidus in twin pregnancy associated with HELLP syndrome. J Perinatal Med 2002;30:273-5. 136. Mak K-H, Chee J-J. Myocardial infarction and HELLP: a case of heightened vasomotor activity. Int J Cardiol 2004;97:151-2. 137. Isler CM, Rinehart BK, Terrone DA, Martin RW, Magann EF, Martin JN Jr. Maternal mortality associated with HELLP syndrome. Am J Obstet Gynecol 1999;181:924-8.

931
138. Ding D-C, Chu T-W, Liu J-Y. Maternal death associated with Eisenmengers syndrome complicated with HELLP syndrome. Int J Obstet Gynecol 2003;83:189-91. 139. Sibai BM, Taslimi MM, el-Nazer A, Amon E, Mabie BC, Ryan GM. Maternal-perinatal outcome associated with HELLP syndrome in severe preeclampsia-eclampsia. Am J Obstet Gynecol 1986;155:501-9. 140. Aslan H, Gul A, Cebeci A. Neonatal outcome in pregnancies after preterm delivery for HELLP syndrome. Gynecol Obstet Invest (Switzerland) 2004;58:96-9. 141. Visser W, Wallenburg HCS. Temporising management of severe preeclampsia with and without the HELLP syndrome. BJOG 1995;102:111-7. 142. Magann EF, Perry KG Jr, Chauhan SP, Graves GR, Blake PG, Martin JN Jr. Neonatal salvage by weeks gestation in pregnancies complicated by HELLP syndrome. J Soc Gynecol Investig 1994;1:206-9. 143. Abramovici D, Friedman SA, Mercer BM, Audibert F, Lao L, Sibai BM. Neonatal outcome in severe preeclampsia at 24 to 26 weeks gestation: does HELLP syndrome matter? Am J Obstet Gynecol 1999;180:221-5. 144. Van Pampus MG, Wolf H, Westenberg SM, van der Post JA, Bonsel GJ, Treers PE. Maternal and perinatal outcome after expectant management of HELLP syndrome compared with preeclampsia without HELLP syndrome. Eur J Obstet Gynecol Reprod Biol 1998;76:31-6. 145. Roelofsen AC, van Pampus MG, Aarnoudse JG. The HELLP syndromedmaternal-fetal outcome and follow up of infants. J Perinat Med 2003;31:201-8. 146. Singhal N, Amin HJ, Pollard JK, Tough SC, Johnston DW, Clark DJ, et al. Maternal HELLP syndrome: perinatal and neurodevelopmental neonatal outcomes for infants weighing less than 1250 g. J Paediatr Child Health 2004;40:121-6. 147. Miles JF, Martin JN Jr, Blake PG, Perry KG Jr, Martin RW, Meeks GR. Postpartum eclampsia: a recurring perinatal dilemma. Obstet Gynecol 1990;76:328-31. 148. Ascarelli MH, Perry KG Jr, Magann EF, May WL, Blake PG, Martin JN Jr. A birth weight of 600 grams: cutpoint on the cusp of perinatal viability in pregnancies delivered very preterm for HELLP syndrome. J Matern Fetal Invest 1997;7:184-7. 149. Qureshi NS, Tomlinson AJ. Prenatal corticosteroid therapy for elevated liver enzyme/low platelet count syndrome: a case report. J Reprod Med 2005;50:64-6. 150. Bush KD, OBrien JM, Barton JR. The utility of uterine artery Doppler investigation in women with the HELLP syndrome. Am J Obstet Gynecol 2001;184:1087-9. 151. Harms K, Rath W, Herting E, Kuhn W. Maternal hemolysis, elevated liver enzymes, low platelet count, and neonatal outcome. Am J Perinatol 1994;12:1-6. 152. Kandler C, Kevekordes B, Zenker M, Kandler M, Beinder E, Lang N, et al. Prognosis of children born to mothers with HELLP syndrome. J Perinat Med 1998;26:486-90. 153. Brune T, Baytar-Dagly B, Hentschel R, Harms E, Louwen F. Infants of mothers with HELLP syndrome compensate intrauterine growth retardation faster than unaected premature infants: does HELLLP change fetal programming? Biol Neonate 2002;82: 174-80. 154. van Runnard Heimel PJ, Franx A, Schobben AFAM, Huijes AJM, Derks JB, Bruinse HW. Corticosteroids, pregnancy and HELLP syndrome: a review. Obstet Gynecol Surv 2004;60:57-70. 155. Heybourne KD, Burke MS, Porreco RP. Prolongation of premature gestation in women with HELLP syndrome. J Reprod Med 1990;35:53-7. 156. Magann EF, Graves GR, Roberts WE, Blake PG, Morison JC, Martin JN Jr. Corticosteroids for enhanced fetal lung maturatio in patients with HELLP syndrome: impact on neonates. Aust N Z J Obstet Gynaecol 1993;33:131-5.

932
157. Magann EF, Martin RW, Isaacs JD, Blake PG, Morrison JC, Martin JN Jr. Corticosteroids for the enhancement of fetal lung maturity: impact on the gravida with preeclampsia and HELLP syndrome. Aust N Z J Obstet Gynaecol 1993;33:127-30. 158. Magann EF, Bass D, Chauhan SP, Sullivan DL, Martin RW, Martin JN Jr. Antepartum corticosteroids: disease stabilization in patients with HELLP syndrome. Am J Obstet Gynecol 1994; 171:1148-53. 159. Magann EF, Perry KG Jr, Meydrech EF, Harris RL, Chauhan SP, Martin JN Jr. Postpartum corticosteroids: accelerated recovery from HELLP syndrome. Am J Obstet Gynecol 1994;171:1154-8. 160. Thiagarajah S, Bourgeois FS, Harbert GM, Caudle MR. Thrombocytopenia in preeclampsia: associated abnormalities and management principles. Am J Obstet Gynecol 1984;150:1-7. 161. Clark SL, Phelan JR, Allen SH, Golde SR. Antepartum reversal of hematologic abnormalities associated with the HELLP syndrome. J Reprod Med 1986;31:70-2. 162. Yeast JD, Coronado S. Hepatic dysfunction, thrombocytopenia and late-onset preeclampsia. J Reprod Med 1987;32:781-4. 163. Isler CM, Barrilleaux PS, Magann EF, Bass JD, Martin JN Jr. A prospective, randomized trial comparing the ecacy of dexamethasone and betamethasone for the treatment of antepartum HELLP syndrome. Am J Obstet Gynecol 2001;184:1332-7. 164. Vigil-DeGracia P, Garcia-Caceres E. Dexamethasone in the postpartum treatment of HELLP syndrome. Int J Gynaecol Obstet 1997;59:217-21. 165. Yalcin OT, Sener T, Hass H, Ozalp S, Okur A. Eects of postpartum corticosteroids in patients with HELLP syndrome. Int J Gynaecol Obstet 1997;61:141-8. 166. Magann EF, Martin JN Jr. Critical care of HELLP syndrome with corticosteroids. Am J Perinatol 2000;17:417-22. 167. Martin JN Jr, Magann EF. High-dose dexamethasone: a promising therapeutic option for HELLP. Contemp Ob Gyn 1999;44: 55-65. 168. Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003;349:831-6. 169. George JN, Vesely SK. Immune thrombocytopenic purpuradlet the treatment t the patient. N Engl J Med 2003;349:903-5. 170. Martin JN Jr, Thigpen BD, Rose CH, Cushman J, Moore A, May WL. Maternal benet of high-dose intravenous corticosteroid therapy for HELLP syndrome. Obstet Gynecol 2003;189: 830-4. 171. Martin JN Jr, Perry KG, Blake PG, May WL, Moore A, Robinette L. Better maternal outcomes are achieved with dexamethasone therapy for postpartum HELLP syndrome. Am J Obstet Gynecol 1997;177:1011-7. 172. Heller CS, Elliott JP. High order multiple pregnancies complicated by HELLP syndrome: a report of four cases with corticosteroid therapy to prolong gestation. J Reprod Med 1997;42:743-6. 173. Tompkins MJ, Thiagarajah S. HELLP syndrome: the benet of corticosteroids. Am J Obstet Gynecol 1999;181:304-9. 174. Fischer T, Krause M, Beinder E, Schlembach D, Rabenbauer B, Wildt L, et al. Prolongation of pregnancy in patients suering from HELLP syndrome. Geburtsh Frauenhielk 1998;59:335-8. 175. OBrien JM, Milligan DA, Barton JR. Impact of high-dose corticosteroid therapy for patients with HELLP syndrome. Am J Obstet Gynecol 2000;183:921-4. 176. Crane JM, Tabarsi B, Hutchens D. The maternal benets of corticosteroids with HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome. J Obstet Gynaecol Can 2003;25:650-5. 177. Varol F, Aydin T, Gucer F. HELLP syndrome and postpartum corticosteroids. Int J Gynaecol Obstet 2001;73:157-9. 178. Mecacci F, Carignani L, Cioni R, Parretti E, Mognosa M, Piccioli A, et al. Time course of recovery and complications of HELLP syndrome with two dierent treatments: heparin or dexamethasone. Thromb Res 2001;102:99-105.

Martin, Rose, and Briery


179. Antenatal corticosteroids revisited: repeat courses. NIH Consens Statement 2000;17:1-100. 180. Calderon EG, Khawar S, Cunningham JA, Russell LD, Alpert MA. Pulmonary artery thrombus and subcapsular hematoma in a patient with HELLP syndrome: a therapeutic conundrum. Am J Med Sci 2002;323:151-4. 181. Martin JN Jr, Thigpen BD, Moore RC, Rose CH, Cushman J, May WL. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol 2005;104:246-54. 182. Tanner B, Ohler WG, Hawighorst S, Shaer U, Knapstein PG. Complications in HELLP syndrome due to peripartal hemostatic disorder. Zentrablbl Gynakol 1996;118:213-20. 183. Wu SQ, Zu XH, Liu HL, Guo SL. Maternal and perinatal prognosis aected by the time of termination of pregnancy in patients with HELLP syndrome. Zonghua Fu Chan Ke Za Zhi 2003;38: 334-6. 184. OBrien JM, Shumate SA, Satchwell SL, Milligan DA, Barton JR. Maternal benets of corticosteroid therapy in patients with HELLP syndrome: impact on the rate of regional anesthesia. Am J Obstet Gynecol 2002;186:475-9. 185. Rose CH, Thigpen BD, Boll JA, Cushman J, May WL, Martin JN Jr. Obstetric implications of antepartum corticosteroid therapy for HELLP syndrome. Obstet Gynecol 2004;104:1011-4. 186. Magann EF, Roberts WE, Perry KG Jr, Chauhan SP, Blake PG, Martin JN Jr. Factors relevant to mode of preterm delivery with HELLP syndrome. Am J Obstet Gynecol 1994;170:1828-34. 187. Barrilleaux PS, Martin JN Jr, Klauser CK, Bufkin L, May WL. Postpartum intravenous dexamethasone for severely preeclamptic patients without hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome: a randomized trial. Obstet Gynecol 2005; 105:843-8. 188. Isler CM, Magann EF, Rinehart BK, Terrone DA, Bass JD, Martin JN Jr. Dexamethasone compared with betamethasone for glucocorticoid treatment of postpartum HELLP syndrome. Int J Gynaecol Obstet 2003;80:291-7. 189. Bar-Lev MRR, Maayan-Metzger A, Matok I, Heyman Z, Sivan E, Kuint J. Short-term outcomes in low birth weight infants following antenatal exposure to betamethasone versus dexamethasone. Obstet Gynecol 2004;104:484-8. 190. Magann EF, Washburne JF, Sullivan CA, Chauhan SP, Morrison JC, Martin JN Jr. Corticosteroid-induced arrest of HELLP syndrome progression in a marginally viable pregnancy. Eur J Obstet Gynecol Reprod Biol 1995;59:217-9. 191. OBoyle JD, Magann EF, Washburne JF, Sullivan CA, Schorr SJ, Morrison JC, et al. Dexamethasone-facilitated postponement of delivery in an extremely preterm pregnancy complicated by HELLP syndrome. Mil Med 1999;164:316-8. 192. Schlembach D, Munz W, Fischer T. Eect of corticosteroids on HELLP syndrome: a case report. J Perinat Med 2000;28: 502-5. 193. Wallace EM, Baker LS. Eect of antenatal betamethasone administration on placental vascular resistance. Lancet 1999;353: 1404-7. 194. Barkehall-Thomas A, Thompson M, Baker LS, Edwards A, Wallace EM. Betamethasone-associated changes in umbilical artery ow velocity waveforms in multiple pregnancies with umbilical artery absent end diastolic ow. Aust N Z J Obstet Gynaecol 2003;43:360-3. 195. Dodic M, Tersteeg M, Jeeries A, Wintour EM, Moritz K. Prolonged low-dose dexamethasone treatment, in early gestation, does not alter blood pressure or renal function in adult sheep. J Endocrin 2003;179:275-80. 196. Geller SE, Rosenberg D, Cox SM, Brown ML, Simonson L, Driscoll CA, et al. The continuum of maternal morbidity and mortality: factors associated with severity. Am J Obstet Gynecol 2001;191:939-44.

Martin, Rose, and Briery


197. Dreyfus M, Tissier I, Ndocko MA, Denoual I, Baldauf JJ, Ritter J. Corticosteroid therapy for conservative management in marginally viable pregnancy complicated by HELLP syndrome. Eur J Obstet Gynecol Reprod Biol 1999;85:233-4. 198. Gardeil F, Ganey G, Morrison JJ. Severe HELLP syndrome remote from term. Ir Med J 2001;94:54. 199. Stefos T, Pachouras N, Mari G, Cosmi E, Lolis D. A case of partial mole and atypical type I triploidy associated with severe HELLP syndrome at 18 weeks gestation. Ultrasound Obstet Gynecol 2002;20:403-4. 200. Chuileannain FN, MacPhail S. HELLP syndrome at 21 weeks gestation in association with trisomy 13. J Obstet Gynaecol 1999; 19:74-5. 201. Fischer T, Tallukat G, Schneider MP, Schlembach D, Munz W, Homuth V. HELLP syndrome in the 18th week of gestation in association with elevated angiotensin AT(1)-receptor autoantibodies. Eur J Obstet Gynecol Reprod Biol 2001;97:255-7. 202. Vidae AC, Pschirrer ER, Mastrobattista JM, Gilstrap LC, Ramin SM. Mirror syndrome: a case report. J Reprod Med 2002; 47:770-4. 203. Antenatal corticosteroid therapy for fetal maturation. ACOG Committee on Obstetric Practice Committee Opinion. Number 273. Washington (DC): The College; 2002. 204. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:S1-22. 205. Vigil-de Gracia P, Silva S, Montufar C, Carrol I, De Los Rios S. Anesthesia in pregnant women with HELLP syndrome. Int J Gynecol Obstet 2001;74:23-7. 206. Roberts WE, Perry KG, Woods JB, Files JC, Blake PG, Martin JN Jr. The intrapartum platelet count in patients with HELLP syndrome: is it predictive of later hemorrhagic complications? Am J Obstet Gynecol 1994;171:799-804. 207. Cetin A, Yurtcu N, Guvenal T, Imir AG, Duran B, Cetin M. The eect of glyceryl trinitrate on hypertension in women with severe preeclampsia. HELLP syndrome and eclampsia. Hypertens Pregnancy 2004;23:37-46. 208. Briggs R, Chari RS, Mercer B, Sibai BM. Postoperative incision complications after cesarean section in patients with antepartum syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP): does delayed primary closure make a dierence? Am J Obstet Gynecol 1996;175:893-6. 209. Selcuk NY, Odabas AR, Centikaya R, Tonbul HZ, San A. Outcome of pregnancies with HELLP syndrome complicated by acute renal failure. Ren Fail 2000;22:319-27. 210. Abraham KA, Kennelly M, Dorman AM, Walshe JJ. Pathogenesis of acute renal failure associated with the HELLP syndrome: a case report and review of the literature. Eur J Obstet Gynecol Reprod Biol 2003;108:99-102. 211. Asrat T, Nageotte MP. Acute renal failure in pregnancy. In: Foley MR, Strong TH Jr, Garite TJ, editors. Obstetric intensive care manual. 2nd ed. New York: Mc-Graw Hill; 2004. p. 184-95. 212. Reck T, Bussenius-Kammerer M, Ott R, Muller V, Beinder E, Hohenberger W. Surgical treatment of HELLP syndrome-associated liver rupturedan update. Eur J Obstet Gynecol Reprod Biol 2001;99:57-65. 213. Rinehart BK, Terrone DA, Magann EF, Martin RW, May WL, Martin JN Jr. Preeclampsia-associated hepatic hemorrhage and rupture: mode of management related to maternal and perinatal outcome. Obstet Gynecol Surv 1999;54:196-202. 214. Barton JR, Sibai BM. Diagnosis and management of hemolysis, elevated liver enzymes, and low platelets syndrome. Clin Perinatol 2004;31:807-33. 215. Juarez-Azpilcueta A, Motta-Martinez E, Montano-Uzcanga A. Hepatic rupture as a maternal complication of hypertensive disease of pregnancy with HELLP syndrome. Gac Med Mex 2003; 139:276-80.

933
216. Aldemir M, Bac B, Tacyildiz I, Yagmur Y, Keles C. Spontaneous liver hematoma and hepatic rupture in HELLP syndrome: report of two cases. Surg Today 2002;32:450-3. 217. Skukla D, Veillon DM, Scott LK, Heldmann M, Lewis DF, Cotelingam JD. Abdominal pain in pregnancy: HELLP syndrome with subcapsular hematoma of the liver. J La State Med Soc 2003;155:77-9. 218. Martin JN Jr, Files JC, Blake PG, Perry KG Jr, Morrison JC, Norman PH. Postpartum plasma exchange for atypical preeclampsia-eclampsia as HELLP syndrome. Am J Obstet Gynecol 1995;172:1107-25. 219. Eckford SD, MacNab JL, Turner ML, Plews D, Liston WA. Plasmapheresis in the management of HELLP syndrome. J Obstet Gynaecol 1998;18:377-9. 220. Julius CJ, Dunn ZL, Blazina JF. HELLP syndrome: laboratory parameters and clinical course in four patients treated with plasma exchange. J Clin Apheresis 1994;9:228-35. 221. Hamada S, Takishita Y, Tamura T, Naka O, Higuchi K, Takahashi H. Plasma exchange in a patient with postpartum HELLP syndrome. J Obstet Gynaecol Res 1996;22:371-4. 222. Mahalati K, Dawson RB, Collina JO, Bell WR, McCrae KR, Martin JN. Persistant pre-eclampsia post partum with elevated liver enzymes and hemolytic uremic syndrome. J Clin Apheresis 1999;14:69-78. 223. Forster JG, Peltonen S, Kaaja R, Lampinen K, Pettila V. Plasma exchange in severe postpartum HELLP syndrome. Acta Anaesthesiol Scand 2002;46:955-8. 224. Lombano F, Kidder MY, Lilly M, Gollin YG, Block BS. Recurrence of microangiopathic hemolytic anemia after apparent recovery from HELLP syndrome: a case report. J Reprod Med 2002;47:875-7. 225. Detti L, Meccaci F, Piccioli A, Ferrarello S, Carignani L, Mello G, et al. Postpartum heparin therapy for patients with the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) is associated with signicant hemorrhagic complications. J Perinatol 2005;25:236-40. 226. Dart BW 4th, Cockerham WT, Torres C, Kipikasa JH, Maxwell RA. A novel use of recominant factor VIIa in HELLP syndrome associated with spontaneous hepatic rupture and abdominal compartment syndrome. J Trauma 2004;57:171-4. 227. Yamamoto H, Nishikawa S, Yamazaki K, Kudo R. Ecacy of haptoglobin administration in the early postoperative course of patients with a diagnosis of HELLP syndrome. J Obstet Gynaecol 2000;20:610-1. 228. Tsatsaris V, Carbonne B, La Tour MD, Cabrol D, Milliez J. Is conservative treatment of HELLP syndrome safe? Eur J Obstet Gynecol Reprod Biol 1998;80:139-41. 229. Jacquemyn Y, Jochems L, Duiker E, Bosmans JL, Van Hoof V, Van Campenhout C. Long-term renal function after HELLP syndrome. Gynecol Obstet Invest 2004;57:117-20. 230. Van Pampus MG, Wolf H, Mayruhu G, Treers PE, Blecker OP. Long-term follow-up in patients with a history of HELLP syndrome. Hypertens Pregnancy 2001;20:15-23. 231. Kidner MC, Flanders-Stepans MB. A model for the HELLP syndrome: the maternal experience. J Obstet Gynecol Neonatal Nurs 2004;33:44-53. 232. Beal JA, Freda MC. A model for the HELLP syndrome: the maternal experience. Am J Matern Child Nurs 2004;29:332. 233. Chames MC, Haddad B, Barton JR, Livingston JC, Sibai BM. Subsequent pregnancy outcome in women with a history of HELLP syndrome at %28 weeks of gestation. Am J Obstet Gynecol 2003;188:1504-7. 234. Sullivan CA, Magann EF, Perry KG Jr, Roberts WE, Blake PG, Martin JN Jr. The recurrence risk of the syndrome of hemolysis, elevated liver enzymes and low platelets (HELLP) in subsequent gestations. Am J Obstet Gynecol 1994;171: 940-3.

934
235. Wilcken B, Leung KC, Hammond J, Kamath R, Leonard JV. Pregnancy and fetal long-chain 3-hydroxyacl coenzyme A dehydrogenase deciency. Lancet 1993;341:407-8. 236. Tyni T, Ekholm E, Pihko H. Pregnancy complications are frequent in long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deciency. Am J Obstet Gynecol 1998;178:603-8. 237. Strauss AW, Bennett MJ, Rinaldo P, Sims HF, OBrien LK, Zhao Y, et al. Inherited long-chain 3-hydroxyacyl-CoA dehydrogenase

Martin, Rose, and Briery


deciency and a fetal-maternal interaction cause maternal liver disease and other pregnancy complications. Semin Perinatol 1999;23: 100-12. 238. den Boer ME, Ijlst L, Wijburg FA, Oostheim W, van Werkhoven MA, van Pampus MG, et al. Heterozygosity for the common LCHAD mutation (1528gOC) is not a major cause of HELLP syndrome and the prevalence of the mutation in the Dutch population is low. Pediatr Res 2000;48:151-4.